

## Immunoexcitotoxicity as the central mechanism of etiopathology and treatment of autism spectrum disorders: A possible role of fluoride and aluminum

Anna Strunecka, Russell L. Blaylock,<sup>1,\*</sup> Jiri Patočka,<sup>2</sup> and Otakar Strunecky<sup>3</sup>

Institute of Medical Biochemistry, Laboratory of Neuropharmacology, 1<sup>st</sup> Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

<sup>1</sup>Theoretical Neurosciences Research, LLC, Ridgeland, Mississippi, USA

<sup>2</sup>Faculty of Health and Social Studies, Institute of Radiology, Toxicology and Civil Protection, University of South Bohemia Ceske Budejovice, Branisovska, Czech Republic

<sup>3</sup>Laboratory of Applied Hydrobiology, University of South Bohemia, Husova tř. 458/102, 370 05 České Budějovice, Czech Republic

Anna Strunecka: [anna.strunecka@gmail.com](mailto:anna.strunecka@gmail.com); Russell L. Blaylock: [blay6307@gmail.com](mailto:blay6307@gmail.com); Jiri Patočka: [toxicology@toxicology.cz](mailto:toxicology@toxicology.cz); Otakar Strunecky: [otakar.strunecky@gmail.com](mailto:otakar.strunecky@gmail.com)

\*Corresponding author

Received 2017 Nov 1; Accepted 2018 Feb 7.

Copyright : © 2018 Surgical Neurology International

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

### Abstract

Our review suggests that most autism spectrum disorder (ASD) risk factors are connected, either directly or indirectly, to immunoexcitotoxicity. Chronic brain inflammation is known to enhance the sensitivity of glutamate receptors and interfere with glutamate removal from the extraneuronal space, where it can trigger excitotoxicity over a prolonged period. Neuroscience studies have clearly shown that sequential systemic immune stimulation can activate the brain's immune system, microglia, and astrocytes, and that with initial immune stimulation, there occurs CNS microglial priming. Children are exposed to such sequential immune stimulation via a growing number of environmental excitotoxins, vaccines, and persistent viral infections. We demonstrate that fluoride and aluminum (Al<sup>3+</sup>) can exacerbate the pathological problems by worsening excitotoxicity and inflammation. While Al<sup>3+</sup> appears among the key suspicious factors of ASD, fluoride is rarely recognized as a causative culprit. A long-term burden of these ubiquitous toxins has several health effects with a striking resemblance to the symptoms of ASD. In addition, their synergistic action in molecules of aluminofluoride complexes can affect cell signaling, neurodevelopment, and CNS functions at several times lower concentrations than either Al<sup>3+</sup> or fluoride acting alone. Our review opens the door to a number of new treatment modes that naturally reduce excitotoxicity and microglial priming.

**Keywords:** Aluminofluoride complexes, aluminum, autism spectrum disorders, cytokines, fluoride, glutamatergic neurotransmission, immunoexcitotoxicity, microglial activation, neurodevelopment

### INTRODUCTION

The mechanisms involved in autism spectrum disorder (ASD) etiopathology are many, but central to these disorders appears to be prolonged and repeated systemic immune activation and excitotoxicity. It has been generally accepted that chronic inflammation is the hallmark of many neurological and neurodegenerative diseases. [10,29,31,68] Studies of autistic patients have confirmed the presence of a number of immune dysfunctions. [164] Inflammation in the brain has been reported, by several groups, in postmortem brain specimens of both young and old individuals with ASD. [24,88,187,264]

The initial reaction to systemic inflammation may be microglial priming or full neurotoxic activation, depending on the intensity of the activating stimulus. It is known that a great number of conditions can lead to the priming/activation of microglia, such as stress, obesity, trauma, infections, sequential vaccination, hypoxia-ischemia, and exposure to certain neurotoxic metals, such as mercury, lead, and aluminum.

Microglia are involved in every aspect of neurodevelopment. [210,258] Full activation of primed microglia leads to a release of high levels of chemokines, cytokines, interferons, and inflammatory prostaglandins, as well as an assortment of excitotoxic amino acids, such as glutamate, aspartate, and quinolinic acid. It becomes evident that numerous cytokines and chemokines play essential roles in neurodevelopment. Significant alterations of these immune mediators during critical periods of brain development can also cause varying degrees of functional brain disruptions, resulting in abnormal connectivity and disrupted cytoarchitecture. Studies of autistic patients report elevations of particular cytokines and the presence of antibrain antibodies. [73,133,259]

There is growing evidence that glutamate and glutamate receptors (GluRs) are involved in neurodevelopment. [55,77,191] Glutamate neurotransmission far surpasses the presence of other neurotransmitters in the brain, accounting for 90% of neurotransmission in the cortex and 50% of the entire brain being glutamatergic. [286]

In 1969, Olney demonstrated that exposure of specific types of neurons to high levels of glutamate caused a delayed death process that involved intense excitation of neuronal activity (excitotoxicity). [183] Excitotoxicity is caused by excess levels of extraneuronal glutamate and overactivation of ionotropic GluRs on neuronal membranes, leading to ionic influx, disruption of energy metabolism, and potential neuronal death. In 2008, Blaylock coined the term immunoexcitotoxicity to describe the interaction of inflammatory mechanisms and excitotoxicity. [25]

In a previous article, we presented evidence that most heterogeneous symptoms of ASD have a common set of events closely connected with dysregulation of glutamatergic neurotransmission in the brain. [33] It has become accepted that the causation of ASDs represents an assortment of genetic predispositions interacting with a number of environmental factors. Two such factors include aluminum and fluoride. Aluminum's free metal cation (Al<sup>3+</sup>) is an experimentally demonstrated neurotoxin whose ability to impact the human nervous system has been known for decades. [23,193,257,270] While Al<sup>3+</sup> appears among the key suspicious factors contribution to ASD, fluoride is rarely recognized as a causative culprit of increasing prevalence of ASD. [171,239,256] Fluoride and Al<sup>3+</sup> are two ubiquitous contaminants of the environment, including water, nutritional substances, cosmetics, and pharmaceutical products.

In areas with fluoridated drinking water, we observe some symptoms of ASD, such as IQ deficits, sleep-pattern disturbance, inflammation, impaired ability of cognition, and learning and behavioral problems in some individuals. Prolonged exposure to fluoride in the prenatal and postnatal stages of development might have toxic effects on the development and metabolism of brain. Moreover, both fluoride and Al<sup>3+</sup> interfere with a number of enzymes, resulting in a significant suppression of cellular energy production and oxidative stress. [237] As pointed out in a previous papers, one must also consider interactions between these two reactive elements within biological systems. [238,240,242] Such interactions occur rapidly, forming aluminofluoride complexes (AlF<sub>x</sub>), which allow them to activate hundreds of G protein-

coupled receptors (GPCR) at several times lower concentrations than either  $Al^{3+}$  or fluoride acting alone. Signaling disorders represent an important disturbance in ASD pathology. Recent studies have also shown that both fluoride and  $Al^{3+}$  individually, as well as when combined, can activate microglia with release of proinflammatory cytokines. A careful review of known environmental and pathological links to ASD indicates that most of their effects are connected to immunotoxic processes. [23,239,240] Despite intensive research, an effective therapy of ASD symptoms supported by evidence-based medicine has not been found. [154] Our hypothesis opens the door to a number of new treatment modes, including the nutritional factors that naturally reduce excitotoxicity and microglial priming.

## MICROGLIAL ACTIVATION IN BRAIN DEVELOPMENT AND AUTISM SPECTRUM DISORDER

Microglia and astrocytes are involved in every aspect of brain development, including synaptogenesis and refinement, synaptic pruning, neuron elimination, angiogenesis, as well as for maintenance, proliferation, differentiation, and migration of progenitor cells. [98,166,190,210,212] Microglia regulate phagocytosis of apoptotic cells, and a slow-down in proliferation and programmed cell death. Cunningham *et al.* noted that in the primate phagocytosis occurred throughout neurogenesis, peaking as neurogenesis neared completion. [58] The microglia not only phagocytosed dead cells and cell processes, but also selected living cells, such as progenitors and even mature neurons, for destruction. This sculpting of the brain is carefully regulated, designed to produce the most functional neural and glial architecture.

Disturbance of microglial activation by immune stimulation during a critical stage can adversely affect synaptogenesis. [21] Pruning by microglia is activity dependent, which suggest that excitotoxic stimulation during this period could also adversely affect brain architecture, such as molding of cortical lamination and cortical minicolumns. Bilbo and Schwarz have shown that activation of brain microglia early in life can have long-term consequences on brain function even into adulthood. [20]

## NEURODEVELOPMENT AND MICROGLIA

Early in brain development a special glial scaffolding network derived from astrocytic cells, is formed called radial glial cells. [109] Progenitor cells, which will form both glia and neurons, migrate along this radial glial network toward the pial surface, eventually to form a multilayer cortex. Microglia play a major role in the migration of these progenitors.

### Development and distribution of microglia in central nervous system

Microglia are derived from yolk sac progenitors that seed the brain around 4.5 weeks of gestation in the human brain and appear only when blood circulation develops. [170] Subsequent studies strongly support a mesodermal origin that corresponds to a selective macrophage population (myeloid precursors). [127] Microglia possess specific antigen expressing profiles, proliferative potentials, morphology subtypes, and functions not present in macrophages. [38] Microglia enter the brain via the meninges and choroid plexus. After arriving in the central nervous system (CNS), these microglial progenitor cells then migrate from the germinal zones to the functional layers of the brain. Migration cues include cytokines and chemokines as well as developmental morphogens, growth factors, and glutamate released from the microglia. The microglia use axons, radial glial cell processes, and perivascular sheaths as migratory scaffolds.

While amoeboid microglia migrate along radial glial cells and white matter in most mammals, in humans, microglia also invade and attach to blood vessels within the cortical parenchyma. [200] Once within the parenchyma, microglia become highly proliferative, especially within the white matter. [112] From the second trimester, in humans, microglia become widely distributed throughout the developing brain, mainly in a ramified form, in which there is a significant downregulation of surface immune receptors. [175] Even so, these microglia are fully capable of initiating full immune activation equal to that of the adult CNS microglia, for example, as when challenged by LPS. Interestingly, in fetal microglia, one sees an exaggerated release of glutamate and other excitatory molecules upon immune stimulation that is beyond that seen in the adult. Later during gestation, microglia assume an amoeboid morphology. [200,208,210]

### Development of six-layered cortex, germinal zones, migration of progenitors to pial surface, and emergence of astrocytes and oligodendroglialcytes

The major germinal zones in the brain during embryogenesis include the ventricular zone (VZ) and the subventricular zone (SVZ) [Figure 1]. Tong and Vidyadaran outlined the major events occurring in the developing mouse cerebral cortex. [258] This included proliferation of neuroepithelial cells, which is integral in forming the multilayered neural plate with the innermost apical layer making up the VZ. The proliferation and differentiation continues with the formation of a second germinal zone, the SVZ. During this period, one sees migration of progenitors toward the pial surface and eventual formation of a six-layered cortex. And finally, we see an emergence of astrocytes and oligodendrocytes during late embryogenesis, which occurs just prior to birth.

### Normal microglial “pruning” of neuropil, differences in microglial distribution by sex, and reason for early appearance in males of autism spectrum disorder

Cunningham *et al.* demonstrated that the size of the neuronal precursor pool was regulated by microglia, principally by phagocytosis. [58] It has been shown that with maternal immune stimulation one sees a reduction in the size of the neuronal precursor pool, again by microglial phagocytosis. [49] Population of the developing brain with microglia varies with sex, with males having a significantly greater number of microglia early after birth (P4–postnatal day) than females in brain regions concerned with cognition, learning, and memory (hippocampus, parietal lobe, and amygdala). [214,215] The onset of the dramatic increase in brain microglia in males coincides with the rise in their testosterone levels, somewhere around E18 (embryonic day 18). As a result, males are more likely to be diagnosed with early onset neurological disorders, such as ASD, dyslexia, and ADHD. [21]

Females were shown to have a greater number of microglia than males, but this appeared later in development (P30–60). Interestingly, they also found that most microglia in the P4 males were of an activated (amoeboid) morphology, whereas the females at P30–60 were more often ramified [Figure 2]. Bilbo also found that expression of numerous cytokines and chemokines, as well as their receptors, changed dramatically during development of the rat brain and were highly sex dependent as well. [215] In humans, females increase the number of their microglia with increasing age. [214,215]

### Microglial population of different brain areas

Microglia colonizes different areas of the brain at significantly different rates. [189] For example, in the rat, the hippocampus, amygdala, and cortex are the first to be populated by glia. The striatum is populated by microglia much later postnatally in the rodent brain. Of interest, is the observation that environmental stress accelerates colonization of microglia into the postnatal brain. [96] It has also been observed that changes in the timing of the switch from amoeboid to ramified microglia [Figure 2] can have a profound effect on neural development. This is because of the important part played by amoeboid microglia in synaptic pruning and phagocytosis of apoptotic neurons.

The neuroepithelial cells are the most primitive neural precursors, which give rise to all neurons, astrocytes, and microglia in the CNS. It is from the neural plate that we see the appearance of radial glia, which share properties with astrocytes. Importantly, these cells have specific glutamate transporters. [158] These cells are common progenitors for neurons, astrocytes, and oligodendrocytes. In mice from E16 (embryonic day 16) until birth, there occurs a switch from neurogenesis to gliogenesis, where radial glia stop producing neurons and begin generating astrocytes and oligodendrocytes. [195] At this stage, radial glia are diminished in most areas of the brain,

except the cerebellum and retina.

New microglia are not derived from entering macrophages/monocytes, but rather are produced within the brain itself.[37] In the newborn, these microglia are highly proliferative. From E12 onward, increasing numbers of microglia are found throughout the developing cortex. The densest population of microglia is seen in the VZ and SVZ at this stage.[234,248] These changes are seen in all primates as well as humans.

### Microglia concentration in cerebellum and autism spectrum disorder

Several studies have shown the cerebellum to be the most involved area of the brain in ASDs.[8,16,123] Vargas *et al.* found extensive damage to the cerebellum in both younger and older autistic cases.[264] As with the cortical areas of the brain, microglia also play a critical role in cerebellar development, which includes neurite outgrowth, synaptic pruning, debris clearance, apoptosis, and axon and dendritic development.[160,186] Likewise, microglia during cerebellar development undergo morphologic alterations, changing from amoeboid to ramified as development proceeds [Figure 2].[21] It is now appreciated that the cerebellum has nonmotor functions that include control of attention, working memory, language, emotional elaboration, reward, and other higher functions.[18,213] The human cerebellum matures postnatally with the greatest acceleration of growth and neural organization during the first two years after birth.[2,39]

### Normal microglial pruning of synaptic connections; Abnormal microglia activation directed by complement tags on synapses leads to abnormal neural development, and miswiring of brain in autism spectrum disorder; positron emission tomography scanning shows areas of microglia activation in autism spectrum disorder patients

Pruning is essential because during early neurodevelopment more synaptic connections are constructed than are ultimately needed by the mature brain. It has been shown that synaptic pruning is activity dependent, during which time large numbers of synapses are eliminated and the remaining ones are strengthened.[116,122,262] During the third week postnatal they also observed increased cell differentiation, cell proliferation, neurite pruning, and synaptic plasticity. In other brain areas, microglia regulate synapses and axons during the second and third postnatal week.[186] Developmental pruning is dependent on the localization of complement tags on synapses chosen for elimination.[235,236] Phagocytic receptors on the microglia (complement receptor 3-CR3/CD11b, CD18/MAC-1) localizes to synaptically enriched areas. Disruption of this signaling results in a sustained deficit, leading to miswiring of the brain. By a yet unknown mechanism weaker synaptic units are tagged for phagocytic removal.

Abnormal activation of microglia and/or the complement system leads to abnormal neural development, as seen in ASD.[235] Microglia are already within the brain when we begin to see neuronal migration, proliferation, and differentiation, and as a result play a major role in the ultimate establishment of functional neural networks by regulating axonal and dendritic pathfinding. Because microglia play multiple roles in brain development and because the programmed changes in morphology are very critical to successful molding of brain architecture, anything that alters this microglial morphological pattern has the potential of significantly altering ultimate brain architecture and brain maturation. It is known that microglial activation is extensive in ASDs.[187,247,264]

Suzuki *et al.* examined twenty men, aged 18–31 with confirmed autism versus matched controls using microglial activation PET scanning techniques utilizing the [<sup>11</sup>C]R-PK11195 tracer.[247] They found extensive microglial activation in several areas of the brains of autistic patients that was not accompanied by microglial proliferation. Microglial activation was significant in the cerebellum, anterior cingulate cortex, orbitofrontal and midfrontal cortical areas, superior temporal and fusiform cortex, and corpus callosum. The most intense activation was in the cerebellum, which conforms to the findings by Vargas *et al.*[264]

### What activates the microglia?

Microglia can be activated by peripheral autoantibodies, as are frequently seen in autistic patients.[230,274] Elevations in peripheral cytokines and chemokines by other mechanisms, such as exposure to neurotoxic metals, certain pesticides/herbicides, stress, trauma, ischemia/hypoxia, and autoimmune disorders, can also activate brain microglia, principally involving IL-1b and tumor necrosis factor-alpha (TNF-α).[28,172]

### Reelin (a glycoprotein in brain development for neural migration)

Reelin is a critical glycoprotein in brain development. Secreted from Cajal–Retzius cell in the marginal zone reelin plays an important role in neuronal migration in the prenatal and early postnatal brain.[255] Reelin also affects synapse formation and function in the postnatal and adult brain, and these functions are reflected in the manifestation of behavioral and cognitive deficits in animals with reduced levels of reelin.[60] Functional forms of reelin are generated by cleaving of the 400 kDa and 300 kDa isoforms to a 180 kDa form. Fatemi *et al.* reported that autistics have significantly low reelin levels.[76]

### Maternal infections can lead to abnormal neural development as in autism spectrum disorder; Is the RELN gene a factor?

Human studies have shown that maternal infections can lead to several abnormalities of neurodevelopment, such as aberrant neural migration, decreased dendritic arborization, and abnormal cytoarchitecture in the adult, possibly related to abnormal reelin levels. Some authors suggested that reelin and *RELN* gene were significantly related with psychiatric disorders including ASD.[46] In 2001, the International Molecular Genetic Study of Autism Consortium (IMGSAC) described a region on chromosome 7q as the peak region for linkage to ASD.[113] Given the role of *RELN* in neurodevelopment and its location at chromosome 7q22, *RELN* quickly emerged as a candidate gene for autism and numerous studies (>15) have investigated the occurrence of ASD risk-associated single nucleotide polymorphism in *RELN*.[138] The studies brought mixed results but like *RELN*, their pathological mechanism remains speculative. Lammert and Howell discussing the possible role of reelin in ASD concluded that *RELN* expression is both spatially and temporally consistent with ASD, which is thought to originate as a neurodevelopmental disorder that persists into postnatal life within brain regions including the neocortex, hippocampus, and cerebellum.[138] Some authors suggest that epigenetic processes may play a role in the regulation of *RELN* in ASD brain.

### CYTOKINES AND CHEMOKINES IN AUTISM SPECTRUM DISORDER AND NEURODEVELOPMENT; AUTISM SPECTRUM DISORDER AND IMMUNE DYSFUNCTIONS AND THE ROLE OF EXCITOTOXICITY IN AUTISM SPECTRUM DISORDER

It becomes evident that several cytokines and chemokines play essential roles in brain development regarding migration of progenitors, differentiation, maturation, dendrite arborization, and synaptogenesis. Significant alterations of these immune mediators during critical periods of brain development can also cause varying degrees of functional brain disruptions as well, resulting in abnormal connectivity and cytoarchitecture. Disturbances of these microglial-derived signaling molecules, such as systemic immune activation, would be expected to alter numerous brain pathways and functional systems.

Studies of autistic patients have confirmed the presence of a number of immune dysfunctions, such as neuroinflammation, brain directed autoantibodies, increased T-cell, NK cells, and macrophage responses.[13,164] One study, involving 20 autistic patients, found impaired production of IFN-γ and IL-2 in CD4+ and CD8+ lymphocytes upon stimulation.[133] Li *et al.* in their study of eight autistic patients compared to eight matched normal controls found significant elevation of proinflammatory cytokines TNF-α, IL-6, and GM-CSF (cerebrospinal fluid), INF-γ and chemokine IL-8 in the brains of the ASD patients and no significant difference in IL-10, IL-4 and IL-5, indicating an inflammatory profile.[144] The greatest increase in the ASD patients in their study was in IL-6 and INF-γ. Importantly, this research indicates that ASD children experience increase reactivity of their peripheral immune system to immune activation and that they also experience priming and activation of their brain microglia in conjunction with systemic immune activation. The Vargas *et al.* study, in which they examined the brains of autistic individuals

up to age 45 years, found continuous extensive microglial activation, especially intense in the cerebellum.[264] Migration of progenitor cells, as well as axons, is critical for building brain cytoarchitecture. Young *et al.* found significantly elevated NF $\kappa$ B, a major transcription factor for TNF- $\alpha$ , in samples of the orbitofrontal cortex of autistic patients.[281] NF $\kappa$ B was significantly enhanced in neurons, astrocytes, and microglia in the specimens, with the greatest increase in astrocytes and microglia. Recent studies have shown that IL-1 $\beta$  can stimulate migration of neurons and guide axonal growth cone turning, essential for forming tangential connections between neuronal columns.[155] TNF- $\alpha$  has also been shown to play a critical role in brain development, but as with other cytokines, depends on careful control of its concentration [Figure 3]. For example, high levels of TNF- $\alpha$  have been shown to inhibit neurite outgrowth and branching in embryonic hippocampal neurons.[176]

Using cerebellar granules cell cultures of individual populations of neurons, Oldeive and Doherty found that TNF- $\alpha$  had highly specific developmental effects on these neurons, depending on the embryonic stage of development.[182] A growing number of studies have demonstrated abnormal systemic immune responses, including elevations of particular cytokines and the presence of antibody in ASD.[88,95,101,187,253] Several studies have similarly demonstrated prolonged priming and activation of brain microglia, lasting even decades in ASDs.[91,139,264]

Together, these observations make a compelling case for a link between sequential systemic immune stimulation and neurobehavioral disorders such as the ASDs. Unfortunately, many studies and discussions have omitted or severely downplayed the role of other microglial components linked to immune destruction, such as excitotoxicity.

## GLUTAMATE'S ROLE IN EXCITOTOXICITY AND AUTISM SPECTRUM DISORDER

In 1957, Lucas and Newhouse observed that mice exposed to high-dose monosodium glutamate (MSG) demonstrated extensive neuronal lesions in the inner layer of retinal neurons.[150] Twelve years later, Olney, after reviewing this original observation, repeated the study and discovered not only similar retinal lesions but also selective brain lesions and delayed death processes that involved intense excitation of neuronal activity.[183] Olney coined the term excitotoxicity to describe the phenomenon. Since the early discovery of excitotoxicity, researchers have carefully worked out the mechanism of excitotoxicity and discovered a series of GluRs with complex structures and intimate interactions among themselves and other neurotransmitters and immune receptors [Figure 4].

## THE GLUTAMATERGIC RECEPTOR SYSTEM – ITS LINK TO AUTISM SPECTRUM DISORDER AND ROLE IN EXCITOTOXICITY: AN OVERVIEW

Subsequent studies confirmed the status of glutamate as a neurotransmitter system and that it involved a number of specific types of receptors. Over 50% of the brain's neurotransmission is via glutamatergic neurotransmission and 90% of cortical neurons utilize glutamate as a neurotransmitter.[286] Several studies have elucidated an array of GluR types, which are defined by the agonists that activate them. The GluRs are classified as ligand-gated ion channels (ionotropic receptors) and GPCR metabotropic receptors (mGluRs).[261,273]

The ionotropic GluRs are the N-methyl-D-aspartate receptors (NMDARs), amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPA), and kainate type receptors (KAR). NMDARs are linked to sodium, potassium, and Ca<sup>2+</sup> channels. It is thought that the entry of excessive Ca<sup>2+</sup> into the neuron plays a major role in the excitotoxic process by triggering cascades of destructive cellular signaling. Glutamate affinity is greater with NMDARs than AMPAR/KARs but AMPARs are faster conducting [Figure 3].

### Glutamate receptor: NMDAR

Each of these receptor types is composed of a variable arrangement of subunits, which determines their biophysical and physiological properties. The NMDARs are composed of a tetrad arrangement of subtype receptor units—GluN1, GluN2A-D, and GluN3A and B (NR1, NR2A-D, and NR3A-B by the older classification system). Distribution of these variously composed NMDARs varies with their location in the brain. During development, there are significant changes in the composition of these subunits. In the mammalian brain, functional NMDARs require a GluN1 (NR1) subunit associated with one or more GluN2 (NR2) subunits. Magnesium (Mg<sup>2+</sup>) sites within NMDAR channels regulate receptor function, with Mg<sup>2+</sup> playing a major role as a voltage-dependent channel blocker. With depolarization, the Mg<sup>2+</sup> block is relieved, allowing the action potential to proceed. Sensitivity to Mg<sup>2+</sup> blockade also varies with subunit composition.

### Glutamate receptor: AMPAR

AMPA receptors are composed of GluA1-4 subunits (GluR1-4 by older nomenclature). The presence of the GluA2 (GluR2) subunit in the compositional structure of the AMPA receptor blocks Ca<sup>2+</sup> entry into the neuron [Figure 3]. [57] AMPAR sensitivity is regulated by the trafficking of AMPARs to the neuronal membrane, either containing GluA2 (GluR2) subunit or lacking the GluA2 subunit. The latter causes the AMPAR to be Ca<sup>2+</sup> permeable. Trafficking of GluA2-lacking AMPARs to the synaptic unit increases glutamate-induced neuronal activation, as occurs physiologically with LTP (long-term potentiation), plasticity, and during neurodevelopment. GluA2-lacking AMPARs, under pathological conditions, can trigger exaggerated excitotoxic damage, as occurs with a number of neurological conditions, especially with inflammation [Figure 5]. [22,78,140]

### Glutamate receptors: Metabotropic receptors (mGluRs)

In addition to the ionotropic GluRs, researchers have identified three major classes of mGluRs with eight subunit types. These receptors operate through G-protein-coupled receptors (GPCRs) via seven transmembrane domains, with an extracellular N-terminal and intracellular COOH terminal domain. Group I mGluRs contain two subtype receptors, mGluR1 and mGluR5, which activate phospholipase C (PLC), producing inositol 1,4,5-trisphosphate, and diacylglycerol (DAG) as second messengers [Figure 5]. This class of mGluRs is principally excitatory, enhancing the excitatory effect of the ionotropic receptors, but under some circumstances can be inhibitory.[71] Groups II and III mGluRs are negatively coupled to adenylyl cyclase and inhibit the excitation of the ionotropic receptors. Group II is composed of mGluR2/3 and Group III is composed of mGluRs 4,6,7,8 subunits.

The mGluRs also vary in location, which affects their physiological effect. Some are close to the postsynaptic density and others occur on the presynaptic axon.[167,174] Group I mGluRs are predominately located postsynaptically where they regulate neuronal excitability. Groups II and III are predominately located presynaptically where they inhibit excitation of neurons. There is a marked variation in the sensitivity of these receptor classes to glutamate. The distribution of mGluRs varies considerably among brain regions and neuron types in the hippocampus.[222] The immense degree of complexity among the various types of GluRs, their heterogeneous distribution, as well as their variable sensitivity to glutamate imparts a high degree of potential variability in functional and pathological reactions to both internal and external environmental conditions. Further complexity and flexibility is imparted by the ability of GluRs to alter their insertion on the synaptic plate by exocytosis/endocytosis, that is, trafficking of receptors and receptor subunits.

## GLUTAMATE AND GLUTAMATE RECEPTORS IN NEURODEVELOPMENT

Glutamate receptors (GluRs) are expressed very early in development and play a vital role in most aspects of neurodevelopment, including brain wiring, synaptogenesis, progenitor migration, differentiation, and maturation of cells.[55] Activation of NMDARs has been shown to activate specific genes controlling neuronal plasticity and neurodevelopment.[91] NMDARs appear to play a major role in neurodevelopment by its control of Ca<sup>2+</sup> levels, with Ca<sup>2+</sup> gradients being especially critical for cell

migrations.[130] Developmental control by NMDARs is directly influenced by their subunit composition. For example, using mouse cerebellar granules cell lines, Tamok *et al.* found that increasing NR2B (GluN2B by the new nomenclature) subunit-containing NMDARs increased migration of granules cells *in vivo* and *in vitro*. [252] NR2C (GluN2C), especially in the cerebellum, also played a major role in neuronal migration in this study.

Within the intermediate germinal zone, a site of precursor cell proliferation, and the cortical plate, where neuronal differentiation occurs following radial migration of the precursors, we see further changes with developmental progression [Figure 1]. Within this area, the radially dispersed neurons express glutamate receptors. There is evidence that NMDARs appear in neurons within the cortical plate soon after migrating from the VZ and that these are fully functional receptors (GluRs). [149] In mice, glutamate has been shown to be a powerful chemoattractant for neuronal migration from the VZ/SVZ. [17] Using ferrets, Herrmann demonstrated that glutamate was present in the VZ, intermediate zone, developing cortical plate, and marginal zone as early as embryonic day 34 (E34), seven days before birth. [106] GluR1 (GluA1- new nomenclature), a subunit of AMPARs, emerged more slowly, with only a few neurons having this subunit in the marginal zone and VZ, but became abundant in the marginal zone and subplate as synaptogenesis begins [Figure 1]. Cells staining for AMPAR subunits increases dramatically during the first two weeks postnatal, reaching maximal levels by the third week. GluR2/3 follow a similar pattern and appear mostly on pyramidal cells.

Furuta and Martin examined sheep neocortex during cortical lamination, specifically for expression of AMPARs (GluR1, GluR2/3 and GluR4), KARs (GluR6/GluR7), and mGluR5. [84] They found that there was distinct, temporal localization of GluRs during neocortical development. They also observed that each GluR had a differential localization within the marginal zone, cortical plate, and subplate. At term, the localizations of the various GluRs changed during cortical plate segregation, which resulted in highly differential distributions within the neocortex at term.

Smith and Thompson, examining the visual cortex of ferrets, found that NMDARs and non-NMDARs follow quite distinct developmental patterns. [233] For instance, NMDARs were low at birth and increased progressively over the first two postnatal months—rising three-fold in layers II/III and nine-fold in layer VI. AMPARs were abundant at birth and their density remained rather constant for the first postnatal month. Their expression reached maximum levels at the period of eye-opening, which occurs on postnatal day 32 in ferrets and soon after birth in humans.

Similar patterns of expression for the various subunits have been confirmed in the developing human brain as well. [202] These studies demonstrate that successful architectonic development of the brain, especially the laminar development of the neocortex, requires a very meticulously controlled pattern of GluR appearance and carefully controlled glutamate levels.

Sodium-dependent glutamate transporters have also been shown to play a major role in neurodevelopment, primarily by controlling glutamate levels, and hence, GluR activation during developmental stages. In humans, there have been five identified glutamate transporters, EAAT1-5. In animal species, GLAST represents EAAT1 and GLT-1, EAAT2. EAAT1 and EAAT2 are present on the cell membranes of microglia, astrocytes, and oligodendrocytes. EAAT1 (GLAST) is the major glutamate transporter in the cerebellum, being mostly expressed in astrocytes. [263] EAAT2 (GLT-1) is the most abundant glutamate transporter in the brain itself, accounting for 90–95% of glutamate uptake in the forebrain. Like EAAT1, it is mostly expressed in astrocytes. While the main function of EAATs is to move extracellular glutamate into glial cells and neurons, under certain conditions one can see reverse transport with movement of glutamate into the extracellular space. [12] This external movement of glutamate from the glia increases the likelihood of excitotoxicity, and in the developing brain, disruption of architectonic development.

Furuta *et al.* found that in the rat, GLAST levels were low prenatally in the forebrain, but were high in Bergmann glia in the cerebellum early postnatally. [85] Levels of GLAST rose in the forebrain later postnatally. EAAT4 was found mainly in the cerebellum, localized to Purkinje cells and levels increased with age. These transporters increased at birth and rose to adult levels between Postnatal day 20 (P20) and Postnatal day 30 (P30). [134]

## GROWTH CONES, GLUTAMATE RECEPTORS, AND CALCIUM GUIDANCE

Growth cones are specialized structures located at the tip of developing axons that act as guidance mechanisms for successful union with synaptic partners. Located at the leading edge of the growth cone are special structures called filopodia and lamellipodia, which guide the axon to its destination among an enormously complex array of possibilities. A number of studies have identified GluRs, in particular NMDARs, within the membrane of growth cones. [69] Once the migration was complete, NMDARs were removed from the growth cone membrane by internal trafficking. Vesicles within axonal growth cones and their filopodia are thought to be able to release glutamate, thus acting through autoreceptors. [209] Glutamate gradients act as chemoguidance signals for circuit construction.

Activation of the growth cone NMDARs produce calcium ( $Ca^{2+}$ ) oscillations that act as guidance signals for axon movement, which includes neuron migration, neurite outgrowth, motility, axon turning, and activation of intracellular signaling pathways involving Rho GTPases, all of which lead to brain architectural construction. [151] There appears to be a permissive range of  $Ca^{2+}$  for growth cone function, with low and high levels inhibiting growth cone extension and activity. [121] Glutamate in low concentrations has been shown to inhibit dendritic outgrowth and dendritic pruning, with higher levels resulting in neuron death, most likely by regulating  $Ca^{2+}$  levels. [163] The cerebral cortex is composed of a series of diverse cytoarchitecturally distinct columns with extensive interconnecting linkages. How these columns form is poorly understood, but recent research suggests that  $Ca^{2+}$  gradients are playing a major role.  $Ca^{2+}$  gradients play a critical role in other developmental functions, such as neuron proliferation, dendrite formation and extension, axon guidance, and growth cone function. [198]  $Ca^{2+}$  also plays a critical role in ending neuronal migration, with a reduction in  $Ca^{2+}$  transients signaling an ending of migration. [135]

Disruption of cortical column cytoarchitecture and connectivity is characteristic of ASDs. For example, Damarla *et al.* examined high functional autistics using a combination of behavioral testing, functional MRIs, functional connectivity, and corpus callosum morphometric methodological tools, and found that autistics had lower functional connectivity between higher order working memory/executive areas and visuospatial regions (between frontal and parietal-occipital regions). [59] Others found functional connectivity defects between the anterior and posterior insula and specific brain regions involved in emotional and sensory processing. [67] A more recent study using DTI imaging described significant abnormalities in white matter development of the cingulum bundle among 21 ASD adolescents compared to 21 age and sex-matched healthy volunteers. [111] They also found lower fractional anisotropy within the cingulum bundle, which was associated with worse behavioral control.

Underconnectivity, with severe changes in many brain structures, has also been shown for the cerebellum, an area of the brain most affected in autism. [56] These severe changes are not seen in postnatal onset ASD. One explanation for the extreme vulnerability of the cerebellum is because it has a much longer developmental period, especially postnatally, than that in the cerebrum. [254] Because of the prolonged developmental period associated with cerebellar development, injuries by environmental agents, inflammation, and excess glutamate become much more likely. [18] This again demonstrates the critical nature of careful regulation of glutamate gradients within the developing neocortex and that abnormal levels of glutamate during critical stages of neurodevelopment can have serious consequences on brain circuit construction. We also see considerable changes in the levels of various neurotransmitters, such as glutamate, aspartate, GABA, glycine, and taurine during cerebellar development, which are temporally regulated. [168] Disturbances in the programmed rise and fall of these neurotransmitters can alter the architectonic development of the brain, especially the cerebellum.

Synaptogenesis and synaptic pruning within the brain follows a programmed timeline that is specific for individual areas of the brain. A recent study found that synaptic density begins to decline at puberty and is completed during adolescence, within the prefrontal cortex. Substantial elimination of synaptic spines continues beyond adolescence, well into the third decade. [53] Dendritic development begins early, with cortical neurons slowly developing dendrites during the first two trimesters of gestation. [132] The earliest formation of dendrites being within the subplate and deeper cortical layers. Dendritic development accelerates from the third trimester

onward and remains highly active until the end of the first postnatal year, making dendritic development vulnerable to radical changes in inflammatory mediators and excitatory neurotransmitters for a considerable period during development. In the human neocortex, dendritic development is most active during infancy and early childhood.[110]  $Ca^{2+}$  signaling, mostly regulated by NMDAR activation, has been shown to play a major role in dendritic growth and branching as well as the formation of dendritic spines.[131] Further, NMDAR signaling, which acts at sites of synaptic contact, plays an important role in dendritic spine formation.

### Glutamate receptors and the cerebellum in autism spectrum disorder

Within the cerebellum, it has been shown that GluA2 receptors, an AMPAR subunit that reduces  $Ca^{2+}$  influx, is required for normal development of Purkinje cell dendrites.[249] It was also shown that excess  $Ca^{2+}$  inhibited dendrite formation and maturation, which would occur with either GluA2-lacking AMPAR insertion and/or overactivity of NMDARs. Increased trafficking of GluA2-lacking AMPARs ( $Ca^{2+}$  permeable) occurs with inflammation.[140] In both instances, excess glutamate within the extraneuronal space could disrupt dendrite formation and result in a dysfunctional brain.

### Glutamate receptors and synapse formation

Presynaptic NMDARs also play a major role in synapse formation, and stabilization. GluN2B (NR2B) is essential for neural pathway construction and is widely expressed in the brain during neurodevelopment.[77] Periods of higher NMDAR expression coincides with periods of intense synaptic formation. Excess glutamate stimulation, as occurs during inflammation and other conditions of intense microglial activation, could switch conditions from one of active synaptic development to synaptic damage. ASDs are typically diagnosed before age 3, which is a period of intense synaptic plasticity.[110] During brain development, especially postnatal development, one sees intense synaptic construction, which in the visual cortex of humans peaks during infancy (around 3 months) and at approximately 15 months postnatal for the prefrontal cortex. Synaptic density gradually decreases thereafter so that synaptic density is reduced somewhere around 40% between puberty and adult age in the macaque monkey, which closely resembles that of humans.[35] Synaptic pruning is highly dependent on GluRs and follows a tightly regulated schedule, as described. Microglia appear to be major players in synaptic pruning both as sources of glutamate and by phagocytosis of neurites and whole neurons.[186] Another critical process occurring during CNS development is switching of GluR subunits. It has been shown that early in development, GluN2B subunit is predominant in brain NMDARs, and that as the brain matures postnatally, there is a switching to GluN2A subunits as found in the adult brain.[102] This switching was shown to play a vital role in the synaptic integration of AMPARs.

### Glutamate receptors: Metabotropic GluRs and neurodevelopment

Metabotropic GluRs have also been shown to play a major role in neurodevelopment.[43] For example, group I mGluRs, which include the subunits mGluR1 and mGluR5, both have a fixed temporal developmental pattern. Early after birth, mGluR 1 levels are low and progressively increase with advancing postnatal development. The opposite pattern is seen with mGluR5, which exist in high levels at birth and progressively declines as the brain matures postnatally. The mGluR5 receptors are more often seen in in zones having active neurogenesis. During the first two weeks of postnatal life one sees high concentrations and widespread mGluR5 activity and responsiveness.[148] Interestingly, mGluR5 is the only mGluR subtype located on embryonic neural stem cells. It is also of interest that mGluR1 activation increases the level of reelin mRNA in cultured cerebellar neurons.[162] An important observation as regards ASDs is that inflammation during fetal development has been shown to reduce reelin levels in the developing brain.

### Glutamate receptors and autism spectrum disorder; A short neurobiochemical summary

Together, these studies strongly suggest that glutamate and its receptors are playing a major role in the progressive elaboration of the architecture of the developing brain and that a number of internal and external environmental conditions can alter both glutamate levels and GluR physiology, resulting in varying degrees of abnormal brain development.

## IMMUNOEXCITOTOXICITY IN BRAIN DEVELOPMENT AND AUTISM SPECTRUM DISORDER

A growing number of studies are defining an interrelationship between the immune system and excitatory neurotransmission. This includes alteration of glutamate transporters as well as direction of glutamate transport, trafficking of  $Ca^{2+}$ -permeable AMPARs and NMDARs, elevation of glutaminase activity, and suppression of mitochondrial function with alteration of mitochondrial energy generation, thus enhancing excitotoxicity [Figure 5].

### FROM ALTERATION OF THE IMMUNE RESPONSE TO GLUTAMATE RECEPTORS TO EXCITOTOXICITY WITH EXCESS GLUTAMATE AS A NEUROTRANSMITTER

One of the principle control systems of extraneuronal levels of glutamate is accomplished by a series of five glutamate transport proteins (EAAT1-5) discussed above. Both inflammatory cytokines and excitotoxins, alter the redox status of EAATs, making them dysfunctional, thus allowing the accumulation of extracellular glutamate and possible excitotoxicity. Extraneuronal glutamate can also be altered by another system called the cystine/glutamate antiporter  $Xc^-$ . Under normal conditions, this system exchanges extracellular cystine for intracellular glutamate, thus raising extracellular glutamate levels, which are then quickly lowered by EAATs [Figure 6]. When the EAATs are rendered dysfunctional by reactive oxygen/reactive nitrogen species (ROS/RNS), 4-hydroxynoneal and pro-inflammatory cytokines, glutamate levels will rise in the extracellular space and trigger excitotoxicity over a prolonged period.

### REPEATED IMMUNE ACTIVATION LEADS TO MICROGLIAL ACTIVATION, EXCESS GLUTAMATE, AND NEUROPATHOLOGICAL CHANGES IN THE NEUROPIL THAT CAN BE BLOCKED BY GLUTAMATE RECEPTOR BLOCKERS

Prolonged and repeated systemic immune activation appears to be central to ASD etiopathology. With subsequent, especially closely spaced immune stimulation, full activation of the overactive primed microglia occurs, leading to progressive pathological changes in the developing brain. This is especially so if the episodes of systemic immune stimulation are closely spaced together.[26] It has been shown that inflammatory cytokines, such as TNF- $\alpha$ , do not cause neuronal destruction by itself, but rather enhance glutamate excitotoxicity [Figure 3]. For example, LPS- or TNF- $\alpha$  stimulates macrophages and microglia to induce robust neurotoxicity, but the destruction was completely blocked by MK-801 (dizoclipine), an NMDAR blocker.[279] Further, they demonstrated that blocking glutaminase, the enzyme that converts glutamine into glutamate [Figure 7], also blocked TNF- $\alpha$  and LPS neurotoxicity, as did blocking gap junctions, a principle exchange system for glutamate release. Bal-Price and Brown demonstrated similar finding using astrocytes and microglia exposed to LPS or interferon- $\gamma$  in which blocking nitric oxide (NO) production induced by the inflammatory cytokines, prevented neurotoxicity.[14] Further, they found that the NO rapidly inhibited mitochondrial respiration and this increased glutamate release from neuronal/astrocytic cultures. Blocking the NMDARs using MK-801 also prevented neuronal death in these same cultures.

### INTEGRATION OF IMMUNE DYSFUNCTION, GLUTAMATE RECEPTOR CHANGES, MICROGLIAL ACTIVATION, AND DISRUPTION OF NEURODEVELOPMENTAL MILESTONES LEADING TO PATHOLOGIC CHANGES IN AUTISM SPECTRUM DISORDER

In most studies, the target was neurodegeneration, yet the effects of elevation of glutamate brain levels during neurodevelopment can occur at concentrations lower than

needed to cause neurodegeneration. This means that microglial activation alone, as long as it is associated with an elevation of glutamate levels, negates the possibility of disrupting neurodevelopmental milestones, particularly if occurring at periods when glutamate levels should fall. This would especially be of concern should inflammation be prolonged and associated glutamate levels were constantly elevated as well, as we see in ASDs.[264] Inflammation has also been shown to enhance excitotoxicity through both NMDA and AMPARs. IL-1 $\beta$ , for example, has been shown to enhance the sensitivity of NMDARs by several mechanisms, including microglial recruitment and activation, and by stimulating NMDAR trafficking to the synaptic membrane.[157,269] It has also been shown that TNF $\alpha$  and glutamate, each in concentrations too low to initiate neurotoxicity, when combined, produce robust neurotoxicity.[79] TNF- $\alpha$  increased glutamate-induced neurotoxicity by a number of mechanisms, such as microglial recruitment, upregulating glutaminase, inhibition of glutamine synthetase, inhibition of EAATs and stimulation of TNFR1, which increases trafficking of GluA2-lacking AMPARs [Figure 3].[143,180]

Of particular interest is the inflammation-induced enhanced trafficking of GluRs and alteration of glutamate subunits, as well as inflammatory cytokine-stimulated endocytosis of GABA receptors, which would shift the balance in the brain toward excitotoxicity. The interaction between immune mediators and GluRs triggers a neurotoxic reaction, which involves the generation of high levels of ROS and RNS, along with LPP. These neurotoxic compounds have been shown to inhibit glutamate transport proteins (EAATs), inhibit metabolic glutamate-clearing enzymes, such as glutamine synthetase (GS), glutamate dehydrogenase (GDH) and glutamic acid dehydrogenase (GAD), as well as interfere with mitochondrial energy generation [Figure 8].

Interestingly, maternal inflammation has also been associated with a significant increase in glutaminase, an increase in NMDAR subunit GluN2 (NR2) expression and impairment of GLT-1 function, all things that trigger excitotoxicity.[284] Because of the interaction between GluRs and their subunits and inflammatory mediators, it is difficult to separate which component of immunoexcitotoxicity is actually playing the most important part in altering neural development and laminar architecture of the cortex. Most papers written on this subject have concentrated on abnormalities induced by excess immune stimulation on architectonic development and this is especially so with studies on ASDs. Yet, the two mechanisms seem to be inextricably linked. As an example, a recent paper by Rossignol and Frye reviewed the literature on inflammation and its relationship to autism but never mentioned excitotoxicity or GluRs dysfunction.[206] Most of the autism literature tends to follow this pattern.[24,41,108,164] Yet, a growing literature strongly suggest a link to abnormalities in glutamate and/or GluR function as major players in ASDs, which includes children, high functioning autism, and adults with autism.[80,223,224,282]

The ability of immune cytokines and other immune mediators of inflammation, to enhance microglial priming/activation and to magnify the excitotoxic potential of GluRs, indicate that the two processes operate together, both physiologically and pathologically.

## THE ROLE OF FLUORIDE AND ALUMINUM IN ETIOLOGY OF AUTISM SPECTRUM DISORDER

A considerable amount of scientific evidence demonstrates that fluoride and Al<sup>3+</sup> can harm a great number of physiological functions, including critical regulatory enzymes, mitochondrial energy production, neurotransmitter and endocrine signaling, brain development, higher CNS functions, and immune system dysfunctions.[42,240]

### FLUORIDE AS A NEUROTOXIN IS IN ENVIRONMENTAL EXCESS IN GROWING YOUNG CHILDREN

Fluoride is a ubiquitous compound found in drinking water (both naturally and added) in many soils, incorporated within edible plant components, and is considered a natural compound. Millions of people live in endemic areas with high concentrations of fluoride in groundwater and in the biosphere. Fluoride exposure is common in fetuses, newborns, and small children. The United States Environmental Protection Agency (EPA) has done both a dose-response analysis and a relative source contribution analysis.[72] This data show that at the 90<sup>th</sup> percentile a third of children between the ages of 6 months and 4 years are getting significantly more fluoride than is considered safe. For infants up to 6 months old receiving infant formula, if the local drinking water fluoride level is higher than 0.8 mg/L, the intake of fluoride will exceed 0.1 mg/kg/day, and this level is 100 times higher than the level found in breast milk (less than 0.001 mg/kg). Many Asian and Latin American countries have reported concentrations of fluoride often exceeding the WHO guideline values of 1.5 mg/L (1 ppm).[72,240]

### EXCESS FLUORIDE AND NEURODEVELOPMENTAL DEFECTS

Fluoride is not an essential element for human growth and development. Prolonged exposure to fluoride in the prenatal and postnatal stages of development might have toxic effects on the development and metabolism of brain. In fluoridated areas, we observe some core symptoms of ASD in some individuals. These include IQ deficits, hypocalcemia, hypomagnesemia, hypothyroidism, sleep-pattern disturbance, inflammation, impaired ability of cognition, learning, and behavioral problems. Blaylock was the first to suggest that excitotoxicity may be a central mechanism of fluoride toxicity.[27] Despite that epidemiological studies have documented fluoride among developmental neurotoxicants, fluoride is not included among the environmental factors influencing the risk of autism.[97,177,206,280] Extensive research provides evidence that fluoride affects life processes from fertilization to ageing, from gene transcription to cognition.[240] In addition to the interpretation of laboratory investigations using isolated cells/tissues or animal models, many epidemiological, ecological, and clinical studies have shown negative effects of fluoride on domestic and laboratory animals and humans.[237,240]

### ALUMINUM AS A NEUROTOXIN

There are a number of Al<sup>3+</sup> sources, such as the drinking water, dietary substances, cosmetics, and the widespread use of Al<sup>3+</sup> in medicine, namely in vaccines. Many investigations show that Al<sup>3+</sup> can elicit impairment of development and immunity; that it acts as a hormonal disruptor, a neurotoxin, and elicits intense and prolonged activation of brain inflammation. Al<sup>3+</sup> toxicity in humans, especially as regards the CNS, has been studied and discussed by several authors [e.g. 23,171,256,271]. It is not surprising that Al<sup>3+</sup> appears among the environmental toxins, which can participate in the etio-pathology of ASD.[4,193,239]

### INCREASE IN EXPOSURE TO ALUMINUM; RELATIONSHIP BETWEEN ALUMINUM EXPOSURE AND INCREASE IN AUTISM SPECTRUM DISORDER

Among the suspected environmental toxins surveyed, Al<sup>3+</sup> and Al<sup>3+</sup>-adjuvants have increasingly correlated positively to the rise in ASD.[172] The trend in Al<sup>3+</sup>-adjuvants exposure is also notable in that very young infants have experienced the largest relative increase in numbers of vaccination from the early 1980s to 2005. In an extensive review, Tomljenovic and Shaw pointed out that 18 Al<sup>3+</sup>-containing adjuvanted vaccines are included in the current pediatric vaccine schedule.[256] They found that (1) children from countries with the highest ASD incidence appear to have the highest exposure to Al<sup>3+</sup> from vaccines; (2) the increase in exposure to Al<sup>3+</sup>-hyperlactacidemia and increased lactate/pyruvate ratio as well as elevated alanine levels in blood and serum of ASD patients [Figure 8].[240]

Several researchers have reported evidence of mitochondrial dysfunction in ASD brain samples compared to controls.[9,45,94,250] If such dysfunction is present at the time of infections and immunizations in young children, the added oxidative stress from immune activation on cellular energy metabolism is likely to be especially critical for the CNS, which is highly dependent on mitochondrial function. Young children who have dysfunctional cellular energy metabolism, therefore, might be more prone to undergo autistic regression between 4 and 30 months of age if they also have infections or immunizations at the same time.

Recently, Delhey *et al.* measured mitochondrial enzyme activity on the one of the largest cohorts of individuals with ASD studied to date with concurrent measurement of symptoms in a subset and found that children with ASD demonstrated significantly greater variation in mitochondrial activity compared to controls.[63] This study

demonstrates, for the first time, that such metabolic variations are related to ASD symptoms.

It has also been demonstrated that suppression of energy generation significantly increases sensitivity to excitotoxicity.[104] Excitotoxicity, as well as inflammation, stimulates the generation of NO by microglia and astrocytes, which directly suppresses mitochondrial function. The mitochondria also act as  $\text{Ca}^{2+}$  buffering systems, which when disturbed can not only increase excitotoxic sensitivity but also, by altering essential  $\text{Ca}^{2+}$  waves, will alter neuronal and glial migration.[237]

One of the best documented biochemical changes in ASD is a decrease in cellular glutathione (GSH), a major intracellular antioxidant, and an increase in oxidized synergistically, can elevate blood and brain glutamate to levels known to cause alterations in the developing brain, as well as initiate brain inflammation, and neurodegeneration. We suggest that both of these ubiquitous environmental toxins have a substantial role in the immunexcitotoxicity and the etiopathology of ASD.

## METABOLIC AND DEVELOPMENTAL EFFECTS OF FLUORIDE

The highly electronegative fluoride ion with the same size and the same valence orbital as oxygen became a useful laboratory tool in our understanding of the biochemical and biophysical mechanisms of enzyme catalysis underlying biological processes such as metabolism and signal transduction.[93,197,204,237] The toxic action of fluoride has been attributed to the fact that it acts as an enzymatic poison, inhibiting activities of many important enzymes such as enolase, lipase, The reduced/oxidized GSH-redox equilibrium regulates a pleiotropic range of functions that includes ROS/RNS scavenging, detoxification, maintaining cell membrane integrity, signal transduction, and apoptosis. Under normal physiologic conditions, glutathione reductase activity is sufficient to maintain the high GSH/GSSG ratio. Excessive intracellular oxidative stress could result in GSSG export to the plasma. Therefore, an increase in plasma GSSH is a strong indicator of intracellular oxidative stress, which may have functional consequences such as increased mitochondrial superoxide production and a chronic inflammatory response.[287]

GSH and GSSG levels are significantly changed in autistic individuals, mainly as the consequence of disturbances in processes of transmethylation/transsulfuration. Plasma concentrations of methionine, S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), adenosine, homocysteine, cystathionine, cysteine, GSH and GSSG have been repeatedly measured in children with autism and found to be disturbed[87,114] [Table 1].

Highly significant ( $P \leq 0.001$ ) decrease of SAM and SAH was also observed in subjects with ASD.[114] These observations were supported by detailed analysis of metabolic and nutritional status of 55 children with ASD ages 5–16 years compared with nonsibling, neurotypical controls ( $n = 44$ ).[3]

Fluoride can contribute to disturbances in GSH homeostasis because it enters the cascade and attaches to the SAH. Fluoride has been identified as an inhibitor of SAH hydrolase.[165] Several reports have indicated that fluoride exposure can reduce the cellular level of GSH and induce oxidative stress in liver, kidney, heart, spleen, and brain.[5,15,19,225,227]

Oxidative stress, which can stimulate microglial activation and immunexcitotoxicity, may lead to neurodevelopmental abnormalities in children by affecting numerous cellular processes, especially via cell signaling and mitochondrial dysfunction.

## THE EFFECTS OF FLUORIDE ON THE BRAIN AND NEURODEVELOPMENT

Numerous animal studies have been published, which have raised a level of concern about the impact of increasing fluoride exposure on the brain of individuals with autism.[19,225,227] Metabolic and mitochondrial defects caused by fluoride may have toxic effects on brain cells, causing neuronal loss and altered modulation of neurotransmission systems. We have shown that mitochondrial dysfunction, oxidative stress, inflammation, and excitotoxicity are key players in the pathogenesis of ASD.[240] Fluoride induces oxidative stress through depletion in the levels of GSH and superoxide dismutase (SOD) with increased levels of lipid peroxidation products (LPP) in the developing brain of rats.[15] In this study, pregnant Wistar rats were dosed with sodium fluoride (20 mg/L) from day one of pregnancy until the pups were aged day 30. Chronic exposure to fluoride resulted in severe behavioral and cognitive impairments. Recently, Adedara *et al.* reported that fluoride from drinking water (15 mg/L) induced oxidative stress markers and decreased GSH levels in the brain of the male rats.[5]

### Human studies validating animal observations of fluoride toxicity

Two studies provided evidence that peripheral markers of oxidative stress observed in plasma and immune cells of subjects with ASD are similarly changed in several brain regions. Chauhan *et al.* found that GSH levels were significantly decreased by 34.2 and 44.6%, with a concomitant increase in the levels of GSSG by 38.2 and 45.5%, respectively, in the cerebellum and temporal cortex from patients with autism compared to the control group.[44] There was also a significant decrease in the levels of total GSH by 32.9% in the cerebellum, and by 43.1% in the temporal cortex of patients with autism. The redox ratio of GSH to GSSG was also significantly decreased by 52.8% in the cerebellum and by 60.8% in the temporal cortex of patients with autism, suggesting GSH redox imbalance in the brains of individuals with autism.

Rose *et al.* examined frozen samples from the cerebellum ( $n = 15$ ) and Brodmann area 22 (BA-22) of the temporal cortex ( $n = 12$ ) from individuals with autism and unaffected controls. GSH and GSH/GSSG were significantly decreased in both the autistic cerebellum and BA-22.[205]

However, unlike systemic cells, brain neurons depend on the transfer of astrocytic generated GSH, which is produced by the glutamate/cystine antiporter  $\text{X}_{c-}$ . The glutamate/cystine antiporter  $\text{X}_{c-}$  is an exchange system involving an exchange of intracellular glutamate for extracellular cystine. Intracellular cystine is broken down into cysteine, which is metabolized to GSH. Cysteine is the rate-limiting substrate for GSH and, along with cystine, it also forms a key redox couple on its own. That is, they act to reduce oxidative stress. High levels of extraneuronal glutamate inhibit the exchange and can lower brain GSH.[142] This increases the vulnerability of the brain to oxidative stress and immunexcitotoxicity.

### Human studies on impaired neural development found in brains of aborted fetuses in an endemic fluorosis area of China by a pathological study and by a IQ assessment study

Based on the research from China, the fetal brain is highly susceptible to fluoride poisoning.[50,51] The fetal blood–brain–barrier (BBB) is immature and readily permeable to fluoride. Elevated fluoride content was found in embryonic brain tissue obtained from government required abortions in areas where fluorosis was prevalent. A study by Du revealed adverse effects of fluoride on the brains of 15 aborted fetuses between the 5–8<sup>th</sup> months of gestation from an endemic fluorosis area in China compared with those from a non-endemic area.[66] These studies showed poor differentiation of brain nerve cells and delayed brain development. One may conclude from these studies of chronic fluoride overload during the course of human intrauterine fetal life that fluoride may produce certain harmful effects on the developing brain of the fetus.

### Meta-analyses studies of intelligence in children with high fluoride exposure

Tang *et al.* published a meta-analysis of 16 studies carried out in China between 1998 and 2008 evaluating the influence of fluoride levels on the IQ of children.[251] These authors concluded that children living in an area with a high incidence of fluorosis and high ambient air fluoride levels have a five times higher odds of developing a low IQ than those who live in a low fluorosis area.

Findings from meta-analyses of 27 studies published over 22 years suggest an inverse association between high fluoride exposure and children's intelligence.[50,51] Children who lived in areas with high fluoride exposure had lower IQ scores than those who lived in low exposure or control areas. These findings are consistent with



Children who lived in areas with high fluoride exposure had lower IQ scores than those who lived in low-exposure or control areas. These findings are consistent with an earlier review, but are more comprehensive in (a) including 9 additional studies, (b) performing meta-regression to estimate the contribution of study characteristics as sources of heterogeneity, and (c) estimating pooled risk ratios for the association between fluoride exposure and a low/marginal Raven's test score.[251]

### More human studies on the inverse association of fluoride exposure and IQ

The team of Fluoride Action Network summarized 57 human studies; 50 of which found that elevated fluoride exposure is associated with reduced IQ and only 7 studies found no such association (<http://fluoridealert.org/studies/brain01/>). The human studies are based on IQ examination of over 12,000 children. Reduction of children's intelligence and various psychiatric symptoms, such as memory impairment, difficulties with concentration and thinking were reported from various geographic regions. Even in studies with methodological limitations, IQ reduction is a consistent conclusion. Many of the fluoride/IQ studies have used relatively simple designs and have failed to adequately control for all factors that can impact a child's intelligence (e.g., parental education, socioeconomic status, lead, and arsenic exposure). For several reasons, however, it is unlikely that these limitations can explain the association between fluoride and IQ. Indeed, the studies that controlled for certain key factors (e.g., arsenic, iodine, etc.) reported some of the largest associations between fluoride and IQ to date. A study from Mexico, which examined 61 children aged 6 to 8 years from a community with 1.2 to 3 ppm of fluoride in their drinking water, found that urinary fluoride correlated positively with reaction time and inversely with the scores in visuospatial organization.[203] The authors concluded that these changes could affect the attention process and the reading and writing abilities in children. Approximately 14 million people live in high-risk areas in Mexico. Significant inverse relationship between the fluoride concentration in drinking water and IQ ( $r$  value =  $-0.204$ ;  $P < 0.000$ ) was reported by several authors in India.[11,125,173] The effect of high water fluoride concentration on the intellectual development of children has been observed in some regions of Iran.[216]

The results from several geographic regions support the view that fluoride may be a developmental neurotoxicant that affects brain development at exposures much below those that can cause toxicity in adults. Serum fluoride concentrations associated with high intakes from drinking water may exceed 1 mg/L (50  $\mu\text{mol/L}$ ) – more than 1,000 times the levels of some other neurotoxicants that cause neurodevelopmental damage.[251]

## FLUORIDE AND ENDOCRINE DISRUPTIONS

### Fluoride and thyroid dysfunction

Disturbance of thyroid hormone production has been found in correlation with lowered IQ in children. The investigations from India demonstrated that the thyroid gland appears to be very sensitive tissue in the body in relation to fluoride burden. Susheela *et al.* compared the production of free thyroid hormones (FT3/FT4) and thyroid-stimulating hormone (TSH) of 90 children living in fluoride endemic, non-iodine deficient areas of Delhi, India, along with 21 children from non-endemic areas.[246] The serum fluoride concentration also had a significant relationship with FT3/FT4 and TSH concentrations in school children in an endemic fluoride area of Udaipur district, Rajasthan.[231]

### Thyroid deficiency leads to brain damage in autism spectrum disorder

Thyroid hormones are essential for brain maturation and for brain function throughout life. Thyroid hormone deficiencies even for short periods, may lead to irreversible brain damage, the consequences of which depend on the specific timing of onset and duration of thyroid hormone deficiency.

Thyroid dysfunction is frequently found in children with ASD.[92,105,107,177,232] Significantly reduced levels of TSH in ASD have been observed by Hashimoto and colleagues, where they examined 41 ASD boys (average age of 5.7 years) compared to 5 typically-developing (TD) boys.[105] Reduced levels of TSH were also observed in blood spots from infants who later were found to have ASD ( $n = 16$  ASD and  $n = 32$  TD; gender not reported), suggesting that TSH levels may be useful as an early biomarker for ASD. TSH levels were also significantly lower in 30 boys with ASD in comparison with and 30 TD typically-developing boys, ages 2–8 years.[232] Recently, Frye *et al.* measured blocking and binding folate receptor autoantibodies (FRAAs) and TSH, FT4, total T3, thyroid-releasing hormone and other metabolites in 87 children with ASD, 84 of whom also underwent behavior and cognition testing and in 42 of whom FRAAs, TSH and FT4 were measured at prenatal and postnatal periods.[83] The results of this study suggest that variations in thyroid function do indeed have an effect on the behavior of children with ASD, although the exact mechanism for this influence is not clear. The authors suggest that it appears that fetal and neonatal exposure to blocking FRAAs could affect the development of the thyroid, potentially making the thyroid less sensitive to TSH.

## FLUORIDE ACCUMULATION IN THE PINEAL GLAND; MELATONIN DEFICIENCY AND AUTISM SPECTRUM DISORDER

Some symptoms of ASD, such as the sleep problems and the early onset of puberty, suggest abnormalities in melatonin physiology and dysfunctions of the pineal gland.[178] Luke[215] reported that fluoride accumulates in the pineal gland and that mongolian gerbils fed higher doses of fluoride excreted less melatonin metabolite in their urine and took a shorter time to reach puberty.[153] Luke analyzed the pineal glands from 11 human corpses, and found that the fluoride in the apatite crystals averaged about 9,000 ppm and in one case went as high as 21,000 ppm.[152] Melatonin is a hormone mainly synthesized in the pineal gland during the night. It is a biological signal of light/dark cycles and is considered as a major circadian synchronization system. Melatonin is responsible for regulating numerous life processes including reproduction, development, and aging. Melatonin has powerful neutralizing effects on ROS and LPP and increases the levels of several of the antioxidant enzymes in the brain. It is also an important modulator of mitochondrial metabolism, digestive functions, and immunity.

Decreased levels of melatonin in blood or urine have been reported as very frequent features in individuals with ASD compared to typically developing controls.[178] Many studies indicate clearly that nocturnal production of melatonin is reduced in ASD. Four studies have observed a correlation between abnormal melatonin concentrations and the severity of autistic behaviors. Babies with the lowest melatonin production had the most neurobehavioral problems.[185,260,266] The disruption of serotonin-N-acetylserotonin-melatonin pathway [Figure 11] has been suggested as a biomarker for ASD.[1,184] Pagan *et al.* assessed plasma melatonin and whole-blood serotonin in 278 patients with ASD, their 506 first-degree relatives (129 unaffected siblings, 199 mothers, and 178 fathers) and 416 sex- and age-matched controls.[184,185] They confirmed a deficit in melatonin in 51% (45–57%) as well as hyperserotonemia in 40% (35–46%) of ASD patients. Biochemical impairments were also observed in the first-degree relatives of patients.

## FLUORIDE AND NEUROINFLAMMATION: EVIDENCE FROM ANIMAL STUDIES

Few have examined the possibility of direct microglial activation by fluoride, despite that Shivarajashankara with colleagues reported in 2003 increased levels of ROS, RNS, and LPP in the blood of experimental animals treated with fluoride.[226] Wistar albino rats were exposed to 30 or 100 ppm fluoride in drinking water during their fetal, weanling and post-weaning stages of life up to puberty. An increase in brain LPP and ROS formation was found after the treatment of male adult Wistar rats with fluoride (10 ppm) for 30 days.[7] An increased immunoreactivity of glial fibrillary acidic protein was observed, which is specifically connected to astrocytes. Yan *et al.* reported that the supplementation of adult rats with high doses of fluoride (60 and 120 mg/L) in drinking water causes the activation of microglia in the hippocampus and cerebral cortex.[277] Fluoride initiates an inflammatory state through the synthesis of proinflammatory cytokines—IL-1B, IL-6, and TNF- $\alpha$ .

In astrocytes, fluoride activates phospholipase C (PLC) and increases intracellular  $\text{Ca}^{2+}$  level. Once activated by fluoride, microglia secrete large concentrations of IL-1 $\beta$  and TNF- $\alpha$ , which can then recruit more microglial activation in a vicious cycle that ultimately leads to neurodegeneration. Likewise, excitotoxins can activate



## lead to neurodegeneration

Many of metabolic and physiological processes are affected by alterations in intracellular  $\text{Ca}^{2+}$  levels.  $G_{aq}$  mediate phospholipase C (PLC)-dependent phosphoinositide hydrolysis, yielding inositol-1,4,5-trisphosphate and diacylglycerol (DAG) as second messengers to trigger both the increase of intracellular  $\text{Ca}^{2+}$  level as well as PKC activation [Figure 5]. Dysregulation of homeostasis of  $\text{Ca}^{2+}$  in the cell plays a major role in excitotoxicity.  $\text{AlF}_4^-$  mimics the effects of  $\text{Ca}^{2+}$  mobilizing hormones by activating the G protein, which couples the hormone receptor to PLC.  $\text{AlF}_4^-$  can evoke the disturbance of  $\text{Ca}^{2+}$  homeostasis, which markedly affects brain development and functions.[240]

It has been, for example, observed that  $\text{Al}^{3+}$ -induced neural degeneration in rats is greatly enhanced when the animals were fed low doses of fluoride. The presence of fluoride caused more  $\text{Al}^{3+}$  to cross the BBB and be deposited in the brain of rats. The formation of  $\text{AlF}_4^-$ , according to experimental evidence, in quantities as little as 1 ppm of fluoride contamination of water supplied to rats led to a greater uptake of  $\text{Al}^{3+}$  into the brain along with the formation of amyloid deposits like those in Alzheimer's disease.[218,265] Strong evidence exists that fluoride could complex with any pre-existing  $\text{Al}^{3+}$  within body fluids to produce  $\text{AlF}_4^-$ . With over half of mothers using infant formula reconstituted using tap water, infant exposure to significant levels of  $\text{AlF}_4^-$  might become an important risk factor in etiopathology of ASD.

### Amplification of false message of $\text{AlF}_4^-$ in signaling cascades

The effects of  $\text{AlF}_4^-$  are amplified by processes of signal transduction [Figure 12]. The principle of amplification of the initial signal during its conversion into a functional response has been a widely accepted tenet in cell physiology. It is evident that  $\text{AlF}_4^-$  is a molecule giving a false message. As G-protein coupled receptors (GPCRs) lie upstream of processes that produce key intracellular second messengers, it does not come as a surprise that the false signal of  $\text{AlF}_4^-$  has the potential to modulate neurodevelopment, brain structure, structural plasticity, as well as higher cerebral functions.

Basically, by mimicking the mechanism that activates G-protein signaling, aluminofluoride can activate several reactions utilizing G-protein signaling, such as metabotropic glutamate receptors. Protein kinases are essential for GPCRs-mediated signal transduction.  $\text{AlF}_4^-$  mimics the transition state of protein phosphorylation. Protein phosphorylation is also important in posttranslational modification of GluRs. The studies of mGluRs show that like many GPCRs they can activate more than a single G protein, can produce various second messengers, and interact with several common protein kinases. The effects of  $\text{AlF}_4^-$  might thus result in numerous pathophysiological consequences at several times lower concentrations than either  $\text{Al}^{3+}$  or fluoride acting alone. Several common protein kinases, including protein kinase A (PKA), PKC, and mitogen-activated protein kinases (MAPKs), directly interact with mGluR1/5, phosphorylate specific serine or threonine sites, and thereby regulate trafficking, distribution, and function of mGluR1/5 receptors.[141]

Ji *et al.*, examined alterations in the activity of cAMP-dependent PKA (Protein Kinase A) and PKC (Protein Kinase C) in postmortem brain tissue samples from the frontal, temporal, parietal, and occipital cortices, and the cerebellum of individuals with regressive autism as compared to age-matched control subjects and autistic subjects without clinical history of regression.[117,118] (For example, Through a series of steps, Protein Kinases lead to the phosphorylation of amino acids and molecules changing their activity leading to other molecular steps.) Neuronal tissues normally have high activity of PKC, but these authors found that PKC activity was significantly decreased by 57.1% in the frontal cortex of subjects with regressive autism, as compared to age-matched control subjects and by 65.8% as compared to non-regressed autistic subjects. The activity of PKC might also reflect the stimulation of the group I mGluRs, which enhances excitotoxicity. These authors suggested that regression in autism may be attributed, in part, to alterations in GPCR-mediated signal transduction involving PKA and PKC in the frontal cortex and that it is possible that both PKC and PKA are affected by a common pathway. According to our explanation, the alterations in protein kinases in some parts of brain in subjects with regressive autism might reflect an intoxication with  $\text{AlF}_4^-$ . The involvement of PKC has also been reported in other conditions such as inflammation, activity in most cases disorders, and oxidative stress, which are reported by several authors as the hallmarks of ASD.[45,75,206] and  $\text{Al}^{3+}$ .

In another trial, Akinrinade *et al.*, treated male adult Wistar rats with low and high doses of fluoride,  $\text{Al}^{3+}$  or a combination of both elemental nutrients and antioxidants, have their effects on brain homogenates.[7] Both  $\text{Al}^{3+}$  and fluoride activated astrocytes, with the greatest activation seen with the high levels of Nobel Laureate in Medicine Arvid Carlsson. Oxidative stress and high levels of lipid peroxidation products (LPP). Even low dose exposure of these two elements can, as we have gained renewed significance in light of recent results may demonstrate a close link between oxidative stress, neuroinflammation, and  $\text{AlF}_4^-$  induced toxicity.

In recent years, our understanding of function of G-protein coupled receptors (GPCRs) has changed from a particular G protein, to versatile machines, capable of various responses to different stimuli. GPCRs are involved in many biological processes, including the function of antioxidants, in reversing the metabolic changes found in

of GPCRs functions is prevalent in human diseases, so that approximately half (estimated) of the population has a deficiency in GPCR function, mental and immune function. Children and adolescents with poor nutritional status are at high risk of developing ASD. The synergistic action of fluoride and micromolar  $\text{Al}^{3+}$  can thus evoke a wide range of symptoms, which can be corrected to a certain extent by dietary measures.[36,257,275] Many of the vitamins used to treat dynamic interactions can explain the clinically heterogeneous symptoms. Vitamins C, E, and D<sub>3</sub> significantly reduce excitotoxicity. Ameliorative effects of vitamins C, E, and D<sub>3</sub> alone, and in combination, are well documented. Vitamins C and E act as antioxidants scavengers of free radicals and peroxides, which accumulate after fluoride exposure. Vitamin E helps conversion of mono- and dehydroascorbic acid to maintain ascorbic acid levels. Oral

**PREVENTION AND AMELIORATION OF FLUORIDE-INDUCED TOXICITY**  
 100 mg/kg body weight/day) and vitamin E (2 mg/0.2 ml olive oil/animal/day) from day 6 to 19 of gestation along with NaF (40 mg/kg body weight/day). Recently, Lyra *et al.* published a study on NaF-induced total percentage of skeletal and visceral abnormalities in rats.[267] Vitamin E was comparatively less effective than vitamin C. A combination of vitamins C, D<sub>3</sub>, and E ameliorates NaF-induced reduction in serum  $\text{Ca}^{2+}$  and phosphorus.[70,100] Toxic effects of fluoride were ameliorated if its exposure was withdrawn for two months. Recovery was also possible by feeding antioxidants (SOD, GSH,  $\beta$ -carotene, and some herbal extracts).  
 for source, [146] A single trial exploring the effectiveness of ascorbic acid (8g/70kg/day) as a supplemental therapy for autism reported a reduction in symptom severity.[65]

Trials exploring the effect of vitamin C in subjects with ASD have not been repeated up until today, but the case reports of scurvy in autistic children are emerging. [156,192]

### Role of vitamin B<sub>6</sub> and vitamin B<sub>12</sub>, in treating immunoexcitotoxicity

Vitamin B<sub>6</sub> can dramatically lower blood and tissue glutamate levels and raise seizure thresholds. High dose of vitamin B<sub>6</sub>'s ability to powerfully inhibit excitotoxicity at least partially explains the often dramatic results reported by Rimland in treating autistic children.[201] Vitamin B<sub>6</sub> has also been shown to lower brain and blood glutamate levels and to raise GABA levels. In addition, along with folate and vitamin B<sub>12</sub>, it reduces homocysteine levels [Figure 9]. Methylcobalamin is a GluR blocker and supplementation with it improves cerebral and cognitive functions.[6,36] Alterations in processes of methylation and transsulfuration have been studied in detail in ASD. James and her colleagues were able to fix the biochemical disruptions through nutritional supplementation with vitamins B<sub>6</sub>, folic acid (reduced form of folate - B<sub>9</sub>), B<sub>12</sub>, and pangamine (B<sub>15</sub>).[115] Frye and Rossignol[82] investigated in double-blind, placebo-controlled studies l-carnitine and a multivitamin containing B vitamins, antioxidants, vitamin E, and Co-enzyme Q10 while non-blinded studies have investigated ubiquinol. Controlled and uncontrolled studies using folic acid have reported marked improvements in core and associated ASD symptoms in some children with ASD.

### Role of vitamin D<sub>3</sub> in treating autism spectrum disorder

Vitamin D<sub>3</sub> deficiency is accounted among the potential environmental risk factors for ASD.[179] Oral supplementation with vitamin D<sub>3</sub> is popular among interventions

for ASD considering its relative safety and cheapness. An enormous body of scientific literature considering the mechanism of vitamin D<sub>3</sub> effects led to a new view on its role in human health. The metabolites of vitamin D<sub>3</sub> act as hormones, regulating a plethora of functions and processes in human body.[129,181]

Saad *et al.* published a controlled RTC study on 122 ASD children and found that 57% of the patients had vitamin D deficiency, and 30% had vitamin D insufficiency.[208] The children received vitamin D<sub>3</sub>(300 IU/kg/day) for 3 months. Collectively, 80.72% (67/83) of patients who received vitamin D<sub>3</sub> treatment had significantly improved outcome, which was mainly in the sections of the CARS and aberrant behavior checklist subscales that measure behavior, stereotypy, eye contact, and attention span. While this study showed that oral supplementation with vitamin D<sub>3</sub> may help improve some symptoms of ASD, Kerley *et al.* reported that on a group of 42 children with ASD in Ireland, vitamin D<sub>3</sub> supplementation had no effect on the primary outcome with limited and inconsistent effects.[124] The children in this study received 2000 IU vitamin D<sub>3</sub> supplementation or placebo daily for 20 weeks. Cieslinska *et al.* studied vitamin D receptor gene polymorphisms associated with ASD.[54] This team found that vitamin D<sub>3</sub> serum levels were not significantly different between ASD and non-ASD children and concluded that this could indicate that the functionality of vitamin D<sub>3</sub> metabolism might be affected and should be considered when studying the development of symptoms among ASD children.

### Role of diets in autism spectrum disorder

Many of the diets now being proposed for autistic children emphasize elimination of foods known to be exceedingly high in excitotoxin additives. They are also low in sugar. Jones *et al.* demonstrated that children respond to glucose challenges with a hypoglycemic response at higher levels of blood glucose than adults.[119] Autistic children have altered energy metabolism and a high incidence of reactive hypoglycemia, which increases their risk of seizures and excitotoxicity.[53]

### Other nutraceuticals that may be of benefit in treating autism spectrum disorder

A number of nutraceuticals have been shown to improve mitochondrial function, including thiamine, riboflavin-5 phosphate, pyridoxal-5 phosphate, ascorbate, acetyl-L-carnitine, pyruvate, malate, CoQ10, curcumin, niacinamide, ketones, DHA, vitamins K, folate and methylcobalamin.[64,99]

Taurine may play a crucial role in the protection of antioxidant system and ATPases against Al<sup>3+</sup>-induced toxicity in brain and blood of rats. Deficiency of taurine in a rat leads to immune activation in the CNS with Purkinje cell loss, microglial activation and astrocytosis, similar to that observed in the ASD brain.[188] Taurine plays an important role in development of the eye and brain, reproduction, immune function, including anti-inflammatory activity, anti-oxidant activity, membrane stabilization and osmoregulation. Taurine concentrations in blood of ASD children have been determined in several laboratories. However, the reports are controversial, with some studies showed lower, no change or higher taurine concentrations in autistic groups compared to controls.[89,188] Nevertheless, Park *et al.* hypothesize that taurine can ameliorate the development of ASD when delivered at the appropriate time and dosage due to its effects on abnormalities of the innate immune system and oxidative stress.[188]

Many parents of children with ASD report that their child has stool with a sand-like appearance. One of the most common causes comes from a lack of bile acid formation in the liver. Taurine conjugates with bile acids and increases their pool size. Some autism intervention specialist therefore recommend supplementation with taurine.

There is a need for a non-invasive method to both reduce the absorption of Al<sup>3+</sup> in the gastrointestinal system and facilitate the excretion of systemic Al<sup>3+</sup> in the urine, especially in children, pregnant mothers and women of childbearing age who may become pregnant. Based on the knowledge that silicon is the natural antagonist to Nil.

### Conflicts of interest

There are no conflicts of interest.

### Footnotes

<http://surgicalneurologyint.com/Immunoexcitotoxicity-as-the-central-mechanism-of-etio-pathology-and-treatment-of-autism-spectrum-disorders-A-possible-role-of-fluoride-and-aluminum/>

Early in

### REFERENCES

- Abdulmir HA, Abdul-Rasheed OF, Abdulghani EA. Low oxytocin and melatonin levels and their possible role in the diagnosis and credibility to the concept of autism spectrum disorder. Saudi Med J. 2016;37:29–36. [PMCID: PMC4724675] [PubMed: 26739971]
- Abraham H, Tornóczy T, Kosztolányi G, Seress L. Cell formation in the cortical layers of the developing human brain. J Child Psychol Psychiatry. 2015;56:1122–1130. [PubMed: 11226755]
- Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, et al. Nutritional. In addition, these mechanisms explain the pathological findings as well, the association with autism severity. Nutr Metab (Lond) 2011;8:34. [PMCID: PMC3339434] [PubMed: 21911111]
- Adams J, Howsmon DP, Kruger U, Geis E, Geln E, Fimbres V, et al. Evidence for widespread activation of microglia and astrocytes. It also explains why ASD has not been fully understood. PLoS One. 2017;12:e0171111. [PubMed: 28411111]
- Adedara IA, Olabiyi BF, Ojuade TD, Idris UF, Oni SO. A program should be evaluated to reduce the excessive stimulation of immature immune system and to replace Al<sup>3+</sup>-induced oxidative damage along the brain-pituitary axis. J Child Psychol Psychiatry. 2015;56:1122–1130. [PubMed: 11226755]
- Akaike A, Tamura Y, Sato Y, Yokota T. Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. Eur J Pharmacol. 1993;241:1–6. [PubMed: 7901032]
- Akinrinade ID, Memudu AE, Ogundele OM, Ajetunmbi OI. Interplay of glia activation and oxidative stress formation in fluoride and aluminium exposure. Pathophysiology. 2015;22:39–48. [PubMed: 25577494]
- Allen G, Courchesne E. Differential effects of developmental cerebellar abnormality on cognitive and motor functions in the cerebellum: An fMRI study of autism. Am J Psychiatry. 2003;160:262–73. [PubMed: 12562572]
- Anitha A, Nakamura K, Thanseem I, Yamada K, Iwayama Y, Toyota T, et al. Brain region-specific altered expression and association of mitochondria-related genes in autism. Mol Autism. 2012;3:12. [PMCID: PMC3528421] [PubMed: 23116158]
- Appel SH, Zhao W, Beers DR, Henkel JS. The microglial motor neuron dialogue in ALS. Acta Myol. 2011;30:4–8. [PMCID: PMC3185827] [PubMed: 21842586]
- Aravind A, Dhanya RS, Narayan A, Sam G, Adarsh VJ, Kiran M. Effect of fluoridated water on intelligence in 10-12-year-old school children. J Int Soc Prev Community Dent. 2016;6:S237–42. [PMCID: PMC5285601] [PubMed: 28217543]

12. Aschner M, Du YL, Gannon M, Kimelberg HK. Methylmercury-induced alterations in excitatory amino acid transport in rat primary astrocyte cultures. *Brain Res.* 1993;602:181–6. [PubMed: 8095428]
13. Ashwood P, Van de Water J. A review of autism and the immune response. *Clin Dev Immunol.* 2004;11:165–74. [PMCID: PMC2270714] [PubMed: 15330453]
14. Bal-Price A, Brown GC. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. *J Neurosci.* 2001;21:6480–91. [PubMed: 11517237]
15. Banala RR, Karnati PR. Vitamin A deficiency: An oxidative stress marker in sodium fluoride (NAF) induced oxidative damage in developing rat brain. *Int J Dev Neurosci.* 2015;47:298–303. [PubMed: 26390955]
16. Bauman PS, Levine SA. The development of children of drug addicts. *Int J Addict.* 1986;21:849–63. [PubMed: 3771015]
17. Behar TN1, Scott CA, Greene CL, Wen X, Smith SV, Maric D, et al. Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. *J Neurosci.* 1999;19:4449–61. [PubMed: 10341246]
18. Bellebaum C, Daum I. Cerebellar involvement in executive control. *Cerebellum.* 2007;6:184–92. [PubMed: 17786814]
19. Bhatnagar M, Rao P, Sushma J, Bhatnagar R. Neurotoxicity of fluoride: Neurodegeneration in hippocampus of female mice. *Indian J Exp Biol.* 2002;40:546–54. [PubMed: 12622200]
20. Bilbo SD, Schwarz JM. Early-life programming of later-life brain and behavior: A critical role for the immune system. *Front Behav Neurosci.* 2009;3:14. [PMCID: PMC2737431] [PubMed: 19738918]
21. Bilbo SD, Smith SH, Schwarz JM. A lifespan approach to neuroinflammatory and cognitive disorders: A critical role for glia. *J Neuroimmune Pharmacol.* 2012;7:24–41. [PMCID: PMC3267003] [PubMed: 21822589]
22. Biou V, Bhattacharyya S, Malenka RC. Endocytosis and recycling of AMPA receptors lacking GluR2/3. *Proc Natl Acad Sci U S A.* 2008;105:1038–43. [PMCID: PMC2242698] [PubMed: 18195348]
23. Bishop NJ, Morley R, Day JP, Lucas A. Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions. *N Engl J Med.* 1997;336:1557–61. [PubMed: 9164811]
24. Bjorklund G, Saad K, Chirumbolo S, Kern JK, Geier DA, Geier MR, et al. Immune dysfunction and neuroinflammation in autism spectrum disorder. *Acta Neurobiol Exp (Wars)* 2016;76:257–68. [PubMed: 28094817]
25. Blaylock RL. A possible central mechanism in autism spectrum disorders, part 1. *Altern Ther Health Med.* 2008;14:46–53. [PubMed: 19043938]
26. Blaylock RL. A possible central mechanism in autism spectrum disorders, part 2: Immunoexcitotoxicity. *Altern Ther Health Med.* 2009;15:60–7. [PubMed: 19161050]
27. Blaylock RL. A possible central mechanism in autism spectrum disorders, part 3: The role of excitotoxin food additives and the synergistic effects of other environmental toxins. *Altern Ther Health Med.* 2009;15:56–60. [PubMed: 19284184]
28. Blaylock RL. Immunology primer for neurosurgeons and neurologists part 2: Innate brain immunity. *Surg Neurol Int.* 2013;4:118. [PMCID: PMC3784951] [PubMed: 24083053]
29. Blaylock RL. Parkinson's Disease: Microglial/Macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration. *Surg Neurol Inter.* 2017;8:65. [PMCID: PMC5421223] [PubMed: 28540131]
30. Blaylock RL. Phytonutrients and metabolic stimulants as protection against neurodegeneration and excitotoxicity. *JAMA.* 2000;283:40–4. [PubMed: 10833333]
31. Blaylock RL, Maroon J. Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy—a unifying hypothesis. *Surg Neurol Inter.* 2011;2:107. [PMCID: PMC3157093] [PubMed: 21886880]
32. Blaylock RL, Maroon J. Natural plant products and extracts that reduce immunoexcitotoxicity-associated neurodegeneration and promote repair within the central nervous system. *Surg Neurol Int.* 2012;3:19. [PMCID: PMC3307240] [PubMed: 22439110]
33. Blaylock RL, Strunecka A. Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders. *Curr Med Chem.* 2009;16:157–70. [PubMed: 19149568]
34. Bondy SC. Prolonged exposure to low levels of aluminum leads to changes associated with brain aging and neurodegeneration. *Toxicology.* 2014;315:1–7. [PubMed: 24189189]
35. Bourgeois JP, Rakic P. Changes of synaptic density in the primary visual cortex of the macaque monkey from fetal to adult stage. *J Neurosci.* 1993;13:2801–20. [PMCID: PMC6576672] [PubMed: 8331373]
36. Bourre JM. Effects of nutrients (in food) on the structure and function of the nervous system: Update on dietary requirements for brain. Part 1: Micronutrients. *J Nutr Health Aging.* 2006;10:377–85. [PubMed: 17066209]
37. Bruttger J, Karram K, Wörtge S, Regen T, Marini F, Hoppmann N, et al. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. *Immunity.* 2015;43:92–106. Bauman PS, Levine SA The development of children of drug addicts *Int J Addict* 1986;21:849-63. [PubMed: 26163371]
38. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. *Nat Neurosci.* 2014;17:131–43. [PMCID: PMC4066672] [PubMed: 24316888]
39. Butts T, Green MJ, Wingate RJ. Development of the cerebellum: Simple steps to make a 'little brain'. *Development.* 2014;141:4031–41. [PubMed: 25336734]
40. Cadusseau J, Ragunathan-Thangarajah N, Surenaud M, Hue S, Authier FJ, Gherardi RK. Selective elevation of circulating CCL2/MCP1 levels in patients with longstanding post-vaccinal macrophagic myofasciitis and ASIA. *Curr Med Chem.* 2014;21:511–7. [PMCID: PMC5103034] [PubMed: 24083602]
41. Careaga M, Ashwood P. Autism spectrum disorders: From immunity to behavior. *Methods Mol Biol.* 2012;934:219–40. [PubMed: 22933149]
42. Carlsson A. Current problems relating to the pharmacology and toxicology of fluorides. *J Swedish Med Assoc.* 1978;14:1338–92.

43. Catania MV, De Socarras H, Penney JB, Young AB. Metabotropic glutamate receptor heterogeneity in rat brain. *Mol Pharmacol*. 1994;45:626–36. [PubMed: 8183241]
44. Chauhan A, Audhya T, Chauhan V. Brain region-specific glutathione redox imbalance in autism. *Neurochem Res*. 2012;37:1681–9. [PubMed: 22528835]
45. Chauhan A, Gu F, Essa MM, Wegiel J, Kaur K, Brown WT, Chauhan V. Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. *J Neurochem*. 2011;117:209–20. [PMCID: PMC4839269] [PubMed: 21250997]
46. Chen N, Bao Y, Xue Y, Sun Y, Hu D, Meng S, et al. Meta-analyses of RELN variants in neuropsychiatric disorders. *Behav Brain Res*. 2017;332:110–9. [PubMed: 28506622]
47. Chen R, Zhao LD, Liu H, Li HH, Ren C, Zhang P, et al. Fluoride induces neuroinflammation and alters Wnt signaling pathway in BV2 microglial cells. *Inflammation*. 2017;40:1123–30. [PubMed: 28405851]
48. Chinoy NJ. Studies on fluoride, aluminium and arsenic toxicity in mammals and amelioration by some antidotes. In: Tripathi G, editor. *Modern Trends in Environmental Biology*. New Delhi: CBS Publishers; 2002. pp. 164–96.
49. Chinoy NJ, Sharma AK. Amelioration of fluoride toxicity by vitamin E and D in reproductive function of male mice. *Fluoride*. 1998;31:203–16.
50. Choi AL, Sun G, Zhang Y, Grandjean P. Developmental fluoride neurotoxicity: A systematic review and meta-analysis. *Environ Health Perspect*. 2012;120:1362–8. [PMCID: PMC3491930] [PubMed: 22820538]
51. Choi AL, Zhang Y, Sun G, Bellinger DC, Wang K, Yang XJ, et al. Association of lifetime exposure to fluoride and cognitive functions in chinese children: A pilot study. *Neurotoxicol Teratol*. 2015;47:96–101. [PubMed: 25446012]
52. Chubuk N, Patel R, Sebastian R, Exler C. The aluminum content of infant formula remains too high. *BMC Pediatr*. 2013;13:162. [PMCID: PMC3851493] [PubMed: 24000000]
53. Chubuk N, Patel R, Sebastian R, Exler C. The aluminum content of infant formula remains too high. *Psychiatry*. 1993;17:765–74. [PubMed: 8255984]
66. Du L. The effect of fluorine on the developing human brain. *Zhonghua Bing Li Xue Za Zhi*. 1992;21:218. republished in *Fluoride* 2008;41:327.30. [PubMed: 1473206]
67. Ebisch SJ, Gallese V, Willems RM, Mantini D, Groen WB, Romani GL, et al. Altered intrinsic functional connectivity of anterior and posterior insula regions in high-functioning participants with autism spectrum disorder. *Hum Brain Mapp*. 2011;32:1013–28. [PubMed: 20645311]
68. Edminson E, Ashwood P, Van de Water J. Autoimmunity, autoantibodies, and autism spectrum disorder. *Biol Psych*. 2017;81:383–90. [PMCID: PMC5373490] [PubMed: 28340985]
69. Ehlers MD, Fung ET, O'Brien RJ, Huganir RL. Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. *J Neurosci*. 2011;31:41R–47R. [PMCID: PMC3179978] [PubMed: 21289536]
82. Frye RE, Rossignol DA. Treatments for biomedical abnormalities associated with autism spectrum disorder. *Front Pediatr*. 2014;2:66. [PMCID: PMC4073259] [PubMed: 25019065]
83. Frye RE, Wynne R, Rose S, Slattery J, Delhey L, Tippett M, et al. Thyroid dysfunction in children with autism spectrum disorder is associated with folate receptor alpha autoimmune disorder. *J Neuroendocrinol*. 2017;29. [PubMed: 28199771]
84. Furuta A, Martin LJ. Laminar segregation of the cortical plate during corticogenesis is accompanied by changes in glutamate receptor expression. *J Neurobiol*. 1999;39:67–80. [PubMed: 10213454]
85. Furuta A, Rothstein JD, Martin LJ. Glutamate transporter protein subtypes are expressed differentially during rat CNS development. *J Neurosci*. 1997;17:8363–75. [PMCID: PMC6573756] [PubMed: 9334410]
86. Garcimartin A, Merino JJ, Santos-López JA, López-Oliva ME, González MP, Sánchez-Muniz FJ, et al. Silicon as neuroprotector or neurotoxic in the human neuroblastoma SH-SY5Y cell line. *Chemosphere*. 2015;135:217–24. [PubMed: 25957141]
87. Geier DA, Kern JK, Garver CR, Adams JB, Audhya T, Geier MR. A prospective study of transsulfuration biomarkers in autistic disorders. *Neurochem Res*. 2012;11:777–807. [PMCID: PMC3677555] [PubMed: 22370873]
76. Fatemi SH, Snow AV, Sary JM, Araghi-Niknam M, Reutiman TJ, Lee S, et al. Reelin signaling is impaired in autism. *Biol Psychiatry*. 2005;57:777–87. [PubMed: 15820235]
77. Fedder KN, Sabo SL. On the role of glutamate in presynaptic development: Possible contributions of presynaptic NMDA receptors. *Biomolecules*. 2015;5:3448–66. [PMCID: PMC4693286] [PubMed: 26694480]
78. Ferguson AR, Bolding KA, Huie JR, Hook MA, Santillano DR, Miranda RC, et al. Group I metabotropic glutamate receptors control metaplasticity of spinal cord learning through a protein kinase C-dependent mechanism. *J Neurosci*. 2008;28:11939–49. [PMCID: PMC2628285] [PubMed: 19005059]
79. Floden AM, Li S, Combs CK. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. *J Neurosci*. 2005;25:2566–75. [PubMed: 15758166] [PubMed: 15758166]
92. Gillberg IC, Gillberg C, Kopp S. Hypothyroidism and autism spectrum disorders. *J Child Psychol Psychiatry*. 1992;33:531–42. [PubMed: 1577897]
93. Gilman AG. G proteins: Transducers of receptor-generated signals. *Annu Rev Biochem*. 1987;56:615–49. [PubMed: 3113327]
94. Ginsberg MR, Rubin RA, Falcone T, Ting AH, Natowicz MR. Brain transcriptional and epigenetic associations with autism. *PLoS One*. 2012;7:e44736. [PMCID: PMC3440365] [PubMed: 22984548]
95. Goines PE, Ashwood P. Cytokine dysregulation in autism spectrum disorders (ASD): Possible role of the environment. *Neurotoxicol Teratol*. 2013;36:67–81. [PMCID: PMC3554862] [PubMed: 22918031]
96. Gomez-Gonzalez B, Escobar A. Prenatal stress alters microglial development and distribution in postnatal rat brain. *Acta Neuropathol*. 2010;119:303–15. [PubMed: 19756668]
97. Grandjean P, Landrigan PJ. Neurobehavioural effects of developmental toxicity. *Lancet Neurol*. 2014;13:330–8. [PMCID: PMC4418502] [PubMed: 24556010]
98. Gregg C, Weiss S. CNTF/LIF/gp130 receptor complex signaling maintains a VZ precursor differentiation gradient in the developing ventral forebrain. *Development*.

- 2005;132:565–78. [PubMed: 15634701]
99. Guevara-Campos J, González-Guevara L, Cauli O. Autism and intellectual disability associated with mitochondrial disease and hyperlactacidemia. *Int J Mol Sci*. 2015;16:3870. [PMCID: PMC4346931] [PubMed: 25679448]
100. Guna-Sherlin DM, Verma RJ. Vitamin D ameliorates fluoride-induced embryotoxicity in pregnant rats. *Neurotoxicol Teratol*. 2001;23:197–201. [PubMed: 11348838]
101. Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, et al. Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. *Nat Commun*. 2014;5:5748. [PMCID: PMC4270294] [PubMed: 25494366]
102. Hamada S, Ogawa I, Yamasaki M, Kiyama Y, Kassai H, Watabe AM, et al. The glutamate receptor GluN2 subunit regulates synaptic trafficking of AMPA receptors in the neonatal mouse brain. *Eur J Neurosci*. 2014;40:3136–46. [PubMed: 25131300]
103. Hamm HE. The many faces of G protein signaling. *J Biol Chem*. 1998;273:669–72. [PubMed: 9422713]
104. Hasel P, McKay S, Qiu J, Hardingham G.E Selective dendritic susceptibility to bioenergetic, excitotoxic and redox perturbations in cortical neurons. *Biochim Biophys Acta*. 2015;1853:2066–76. [PMCID: PMC4547083] [PubMed: 25541281]
105. Hashimoto T, Aihara R, Tayama M, Miyazaki M, Shirakawa Y, Kuroda Y. Reduced thyroid-stimulating hormone response to thyrotropin-releasing hormone in autistic boys. *Dev Med Child Neurol*. 1991;33:313–9. [PubMed: 1904373]
106. Herrmann K. Differential distribution of AMPA receptors and glutamate during pre- and postnatal development in the visual cortex of ferrets. *J Comp Neurol*. 1996;375:1–17. [PubMed: 8913890]
107. Hoshiko S, Grether JK, Windham GC, Smith D, Fessel K. Are thyroid hormone concentrations at birth associated with subsequent autism diagnosis? *Autism Res*. 2011;4:456–63. [PubMed: 21882364]
108. Hsiao EY. Immune dysregulation in autism spectrum disorder. *Int Rev Neurobiol*. 2013;113:269–302. [PubMed: 24290389]
109. Huttenlocher PR. Morphometric study of human cerebral cortex development. *Neuropsychologia*. 1990;28:517–27. [PubMed: 2203993]
110. Huttenlocher PR, Dabholkar AS. Regional differences in synaptogenesis in human cerebral cortex. *J Comp Neurol*. 1997;387:167–78. [PubMed: 9336221]
111. Ikuta T, Shafritz KM, Bregman J, Peters BD, Gruner P, Malhotra AK, et al. Abnormal cingulum bundle development in autism: A probabilistic tractography study. *Psychiatry Res*. 2014;221:63–8. [PMCID: PMC3918471] [PubMed: 24231056]
112. Imamoto K, Leblond CP. Radioautographic investigation of gliogenesis in the corpus callosum of young rats. *J Comp Neurol*. 1978;180:139–63. [PubMed: 649786]
113. International Molecular Genetic Study of Autism. C. A genomewide screen for autism: Strong evidence for linkage to chromosomes 2q, 7q, and 16p. *Am J Hum Genet*. 2001;69:570–81. [PMCID: PMC1235486] [PubMed: 11481586]
114. James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. *Am J Clin Nutr*. 2004;80:1611–7. [PubMed: 15585776]
115. James SJ, Melnyk S, Fuchs G, Reid T, Jernigan S, Pavliv O, et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. *Am J Clin Nutr*. 2009;89:425–30. [PMCID: PMC2647708] [PubMed: 19056591]
116. Ji K, Akgul G, Wollmuth LP, Tsirka SE. Microglia actively regulate the number of functional synapses. *PLoS One*. 2013;8:e56293. [PMCID: PMC3564799] [PubMed: 23393609]
117. Ji L, Chauhan A, Chauhan V. Reduced activity of protein kinase C in the frontal cortex of subjects with regressive autism: Relationship with developmental abnormalities. *Int J Biol Sci*. 2012;8:1075–84. [PMCID: PMC3432855] [PubMed: 22949890]
118. Ji L, Chauhan V, Flory MJ, Chauhan A. Brain region-specific decrease in the activity and expression of protein kinase A in the frontal cortex of regressive autism. *PLoS One*. 2011;6:e23751. [PMCID: PMC3166116] [PubMed: 21909354]
119. Jones TW, Borg WP, Boulware SD, McCarthy G, Sherwin RS, Tamborlane WV. Enhanced adrenomedullary response and increased susceptibility to neuroglycopenia: Mechanisms underlying the adverse effects of sugar ingestion in healthy children. *J Pediatr*. 1995;126:171–7. [PubMed: 7844661]
120. Kaluzna-Czaplinska J, Jozwik-Pruska J, Chirumbolo S, Bjorklund G. Tryptophan status in autism spectrum disorder and the influence of supplementation on its level. *Metab Brain Dis*. 2017;32:1585–93. [PMCID: PMC5596045] [PubMed: 28608247]
121. Kater SB, Mills LR. Regulation of growth cone behavior by calcium. *J Neurosci*. 1991;11:891–9. [PMCID: PMC6575390] [PubMed: 2010811]
122. Katz LC, Shatz CJ. Synaptic activity and the construction of cortical circuits. *Science*. 1996;274:1133–8. [PubMed: 8895456]
123. Kemper TL, Bauman ML. Neuropathology of infantile autism. *Mol Psychiatry*. 2002;7(Suppl 2):S12–3. [PubMed: 12142934]
124. Kerley CP, Power C, Gallagher L, Coghlan D. Lack of effect of vitamin D3 supplementation in autism: A 20-week, placebo-controlled rct. *Arch Dis Child*. 2017;102:1030–6. [PubMed: 28626020]
125. Khan SA, Singh RK, Navit S, Chadha D, Johri N, Navit P, et al. Relationship between dental fluorosis and intelligence quotient of school going children in and around lucknow district: A cross-sectional study. *J Clin Diagn Res*. 2015;9:ZC10–5. [PMCID: PMC4668514] [PubMed: 26673535]
126. Khan Z, Combadière C, Authier FJ, Itier V, Lux F, Exley C, et al. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. *BMC Med*. 2004;14:975–85. [PubMed: 15390174]
135. Kumada T, Komuro H. Completion of neuronal migration regulated by loss of Ca(2+) transients. *Proc Natl Acad Sci USA*. 2004;101:8479–84. [PMCID: PMC420419] [PubMed: 15150416]
136. Kumar V, Bal A, Gill KD. Impairment of mitochondrial energy metabolism in different regions of rat brain following chronic exposure to aluminium. *Brain Res*. 2008;1232:94–103. [PubMed: 18691561]
137. Kumar V, Gill KD. Oxidative stress and mitochondrial dysfunction in aluminium neurotoxicity and its amelioration: A review. *Neurotoxicology*. 2014;41:154–66. [PubMed: 24560992]

138. Lammert DB, Howell BW. *RELN* mutations in autism spectrum disorder. *Front Cell Neurosci*. 2016;10:84. [PMCID: PMC4814460] [PubMed: 27064498]
139. Lee AS, Azmitia EC, Whitaker-Azmitia PM. Developmental microglial priming in postmortem autism spectrum disorder temporal cortex. *Brain Behav Immun*. 2017;62:193–202. [PubMed: 28159644]
140. Leonoudakis D, Zhao P, Beattie EC. Rapid tumor necrosis factor alpha-induced exocytosis of glutamate receptor 2-lacking AMPA receptors to extrasynaptic plasma membrane potentiates excitotoxicity. *J Neurosci*. 2008;28:2119–30. [PMCID: PMC6671833] [PubMed: 18305246]
141. Leung CCY, Wong YH. Role of G protein-coupled receptors in the regulation of structural plasticity and cognitive function. *Molecules*. 2017;22 [PubMed: 28737723]
142. Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, et al. The cystine/glutamate antiporter system x(c<sup>-</sup>) in health and disease: From molecular mechanisms to novel therapeutic opportunities. *Antioxid Redox Signal*. 2013;18:522–55. [PMCID: PMC3545354] [PubMed: 22667998]
143. Lewitus GM, Pribram H, Duseja R, St-Hilaire M, Stellwagen D. An adaptive role of TNF-alpha in the regulation of striatal synapses. *J Neurosci*. 2014;34:6146–55. [PMCID: PMC6608116] [PubMed: 24790185]
144. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al. Elevated immune response in the brain of autistic patients. *J Neuroimmunol*. 2009;207:111–6. [PMCID: PMC2770268] [PubMed: 19157572]
145. Li YJ, Ou JJ, Li YM, Xiang DX. Dietary supplement for core symptoms of autism spectrum disorder: Where are we now and where should we go? *Front Psychiatry*. 2017;8:155. [PMCID: PMC5572332] [PubMed: 28878697]
146. Liu R, Liu IY, Bi X, Thompson RF, Doctrow SR, Malfroy B, et al. Reversal of age related learning deficits and brain oxidative stress in mice with superoxide dismutase/catalase mimetics. *Proc Natl Acad Sci USA*. 2003;128:15103. [PMCID: PMC166262] [PubMed: 12815103]
147. Lombard J. Autism: A mitochondrial disorder? *Med Hypotheses*. 1998;50:497–500. [PubMed: 9710323]
148. López-Bendito G, Shigemoto R, Fairén A, Luján R. Differential distribution of group I metabotropic glutamate receptors during rat cortical development. *Cereb Cortex*. 2002;12:625–38. [PubMed: 12003862]
149. LoTurco JJ, Blanton MG, Kriegstein AR. Initial expression and endogenous activation of NMDA channels in early neocortical development. *J Neurosci*. 1991;11:792–9. [PMCID: PMC6575351] [PubMed: 1825846]
150. Lucas DR, Newhouse JP. The toxic effect of sodium l-histamate on the inner layers of the retina. *AMA Arch Ophthalmol*. 1957;58:193–201. [PubMed: 13443577]

amate in the human brain. *Neuroscientist*. 2002;8:562–73. [PubMed: 12467378]

S. Gingival bleeding in a patient with autism spectrum disorder: A key finding leading to a diagnosis of scurvy. *Quintessence Int*. 6889]

al and synthetic neurotoxins in our environment: From Alzheimer's disease (AD) to autism spectrum disorder (ASD) *J Alzheimers Dis* [PMCID: PMC5059837] [PubMed: 27747136]

obilization of aluminum into the biosphere. *Front Neurol*. 2014;5:262. [PMCID: PMC4259105] [PubMed: 25538680]

K, He W, Capela A, Davis AA, et al. Timing of CNS cell generation: A programmed sequence of neuron and glial cell production from s. *Neuron*. 2000;28:69–80. [PubMed: 11086984]

T, Zhang Z. Potential protection of taurine on antioxidant system and ATPase in brain and blood of rats exposed to aluminum. 4. [PubMed: 25967032]

ormation of a cyclic adenine ribonucleotide by tissue particles. *J Biol Chem*. 1958;232:1065–76. [PubMed: 13540

o P. Bidirectional radial Ca<sup>2+</sup> activity regulates neurogenesis and migration during early cortical colon affects the pattern of cell division of rat cortical precursors. *Mech Dev*. 24771444] [PubMed: 26933693]

R, Gutteridge J. Aluminium-adjuvanted vaccines transiently increase aluminium IgE. Savic-Radojevic A, Lecic-Tosevski D, Simic T, et al. Impaired redox control in autism spectrum 913] *J Neuroinflammation*. 2014;11:114.

ion of the developing human brain and spinal cord by microglia. van Rooijen N, Mallat M. Microglia promote the death of developing Purkinje cells. *Neuron*. 2004;41:535–47.

in B6 and magnesium in treating autism: Reptexes of Al<sup>3+</sup> and F<sup>-</sup> with a third ligand. *Coordination Chem Rev*. 1996;149:23–32.

an JR, López-Bendito G, Luján R, Shigemoto R, Fairén A, Valdeolmillos M. Cajal-Retzius cells in early postnatal mouse cortex selectively express r-Woodruff JH. Ontogeny of metabotropic glutamate receptors. *Eur J Neurosci*. 2001;13:1147–54. [PubMed: 11285012] 34999]

ME, Carrizales L, Morales R, Calderon J. Decreased intelligence in children and exposure to fluoride and arsenic in drinking water. pl 4):S579–587. [PubMed: 18038039]

ignal transduction: Evolution of an idea. *BioSci Rep*. 1995;15:117–33. [PubMed: 7579038]

), Bai S, Nick TG, Frye RE, et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the 012;2:e134. [PMCID: PMC3410618] [PubMed: 22781167]

vidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism. *Front Physiol*. 206] [PubMed: 24795645]

tochondrial dysfunction in autism spectrum disorders: A systematic review and meta-analysis. *Mol Psychiatry*. 2012;17:290–314. d: 21263444]

, Elserogy YM, Al-Atram AA, El-Houfey AA, Othman HA, et al. Effects of microglia on neurogenesis. *Glia*. 2015;63:1394–405. d: 26010551]

reviews say about interventions for autism

Neuroinflammation. 2014;11:114.

Autism Dev Disord. 2016;46:1464–70.

in the modulation of neurotoxicity. *Neuroimmunomodulation*.

Mech Dev. 24771444] [PubMed: 26933693]

J Neuroinflammation. 2014;11:114.

Neuron. 2004;41:535–47.

Coordination Chem Rev. 1996;149:23–32.

Eur J Neurosci. 2001;13:1147–54. [PubMed: 11285012]

Brain Res.

use by fluorine-containing adenosine

Int J

10736372]

id neurotransmitters during mouse





tem Med Biol. 2013;21:220-9. [PubMed: 25219309]

doni F, Vezzani A, Behrens MM, Bartfai T, et al. Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase of kinases. J Neurosci. 2003;23:8692-700. [PubMed: 14507968]

nprised of aluminum-rich cells that lack microtubules may be associated with the cognitive deficit of Alzheimer's disease. 69. [PubMed: 19591863]

firmment in aged rats chronically exposed to human range dietary aluminum equivalents. Neurotoxicology. 2009;30:182-93. [PubMed:

s S. Mammalian G proteins and their cell type specific functions. Physiol Rev. 2005;85:1159-204. [PubMed: 16183910]

side might connect to

Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci. 2013;9:948-59. [PMCID: PMC3805900]

PMC4133642 [PubMed: 24578174]

t J, Ashwood P, Amaral DG, Van de Water J. Detection of autoantibodies to neural cells of the cerebellum in a ratio as a marker for oxidative stress in paediatric Brain Behav Immun. 2009;23:64-74. [PMCID: PMC2660333] [PubMed: 18706993]


ns of complementary and alternative medical therapy use in children diagnosed with autism 395]

io S, Hayashi M, Nishi T, Yamamoto A, et al. Metabotropic glutamate rec- 2056-62. [PubMed: 9482792]

z F, Song Y, Yan N, et al. JNK and NADPH oxidase invol- 4CID: PMC3773420 [PubMed: 24072958]


Wang F, Wang Z, et al. Fluoride-induce- 1. [PubMed: 26253724]

Li, Liang J, Mizuno T, S- tors. Life Sci. 200



[Open in a separate window](#)


and Neurodevelopment. This illustration demonstrates how microglia plays a major role in all stages of neurodevelopment, by a programed release of cytokines and chemokines, a ed release of glutamate and by active phagocytosis of excessive synaptic units, neurites and even whole cells. Acting at each of the germinal zones, VZ, IZ and CP, microglia controls ration, migration, angiogenesis, synaptogenesis, and dendritic and axonal development






[Open in a separate window](#)


Priming and Full Activation by Sequential Immune Stimulation. Demonstrating the transition from a resting (ramified) microglial phenotype to a primed phenotype by an initial stimulus. Primed microglia have enhancement of cytokine generation, but no release of cytokines or excitotoxins. The second stimulus fully activates the microglia, resulting in a severe immunexcitotoxic reaction




and Immunoexcitotoxicity This chart demonstrates how  $TNF-\alpha$ , through one of its receptors (TNFR1) and via oxidative injury, is linked to enhanced excitotoxicity. This involves inhibition of GS, trafficking of GluA2-lacking AMPARs, upregulation of glutaminase, impaired glutamate transport and endocytosis of GABA receptors.




and Aluminofluoride link to excitotoxicity. This diagram demonstrates stimulation of systemic immune activation and microglial activation within the brain by aluminum and fluoride as well as aluminofluoride.  $Al^{3+}$ ,  $F^-$  and  $AlF_4^-$  all suppresses mitochondrial energy production and trigger ROS/RNS and LPP generation both directly and indirectly via microglial inflammatory cytokines, ROS/RNS, LPP and excitotoxicity. This can produce all the core features of ASD






[Open in a separate window](#)

ubunit Trafficking. Illustration of the pre- and post-synaptic units, demonstrating modulation of synaptic strength by trafficking of AMPA and NMDA subunits to the synaptic cleft. Trafficking of GluA2 (Glu2B)-lacking AMPARs, converts the AMPAR into a calcium permeable receptor, greatly increasing its excitatory strength. Presence of the GluA2 receptor blocks calcium permeability. Inflammation converts AMPARs to the calcium permeable form




ed scheme of the phosphoinositide signaling system. Phosphatidylinositol 4,5-bisphosphate (PIP<sub>2</sub>) in the plasma membrane is hydrolyzed by phospholipase C (PLC) after GPCR and yields inositol 1,4,5-trisphosphate (Ins(1,4,5)P<sub>3</sub>) and diacylglycerol (DAG). Both products of this hydrolysis have a second messenger role. Ins(1,4,5)P<sub>3</sub> binds to a receptor in the membrane of endoplasmic reticulum, which results in a release of Ca<sup>2+</sup> into the cytosol. DAG activates protein kinase C (PKC). The coupling between the GPCR and PLC is mediated by Gβγ – phosphatidic acid, PI – phosphatidylinositol.



these levels we see enzymatic conversion of glutamine into glutamate with protective systems to prevent excessive accumulation of glutamate by entry into kreb's cycle and by conversion into GABA



of mitochondrial energy metabolism in ASD. Patients with ASD have raised blood lactate, alanine, and glutamate. LDH – lactate dehydrogenase; ALT –




[Open in a separate window](#)

of the processes of transmethylation/transsulfuration metabolism. SAM – adenosylmethionine, SAH – S-adenosylhomocysteine, GSH – reduced form of glutathione, (GR).

abolites of methionine-homocysteine cycle in ASD children

	ASD children Geier <i>et al.</i> (n)	Healthy controls Geier <i>et al.</i> (n)	ASD children James <i>et al.</i> n=80	Healthy controls James <i>et al.</i> n=73	Reference values for children and youth
μmol/L)	17.6 (28)	31.5	20.6 ± 5.2	28.0 ± 6.5	28
)	3.1 ± 0.53 (38)	4.2 ± 0.72 (120)	1.4 ± 0.5	2.2 ± 0.9	4.2 ± 0.74
L)	0.46 ± 0.16 (38)	0.35 ± 0.05 (120)	0.4 ± 0.2	0.24 ± 0.1	0.2 ± 0.26
ie (μmol/L)	5.87 (12)	9.46 (120)	5.7 ± 1.2	6.0 ± 1.3	4.3-10
l/L)	48.6 ± 14.0 (38)	97.5 ± 8.8 (27)	-	-	95 ± 9
ol/L)	17.8 ± 9.5 (38)	23.2 ± 4.2 (64)	165 ± 14	207 ± 22	238 ± 22


measured the free plasma cysteine, while James *et al.*<sup>[104]</sup> probably used the value for total cysteine. However, the both values indicate the decrease of cysteine in



Its message is greatly amplified during the conversion into the functional response of a cell.  $\delta$ -opioid N-acetyltransferase and hydroxyindole O-methyltransferase could be cAMP, inositol 1,4,5-trisphosphate and diacylglycerol

ptoms

Special supplements and compounds, which



reduce	activation
Pyridoxal-5 phosphate (vitamin B <sub>6</sub> )	Magnesium glycinate, lactate or threonate
Methylcobalamin (vitamin B <sub>12</sub> )	Zinc
Folic acid, folate (vitamin B <sub>9</sub> )	Silicon-rich mineral waters
Tri- or Dimethylglycine (vitamin B <sub>15</sub> )	Melatonin
Vitamin E (mixed tocopherols)	GSH
Vitamin C (buffered)	Taurine
Vitamin D3	Tryptophan
Coenzyme Q10	Flavonoids - quercetin
Acetyl-L-carnitine	Baicalein
Alpha-lipoic acid	Resveratrol
DHA/EPA- omega3 fatty acids	Curcumin

rgical Neurology International are provided here courtesy of **Wolters Kluwer -- Medknow Publications**